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Glioblastoma Multiforme (GBM) is a highly aggressive brain tumor for which there is no 
treatment. Oncolytic Viruses (OVs) are attenuated tumor-selective viruses designed to replicate 
in and kill tumor cells without affecting normal tissue. Herpes Simplex Virus type-1 derived 
oncolytic vectors (oHSV-1) are a promising and safe alternative to current GBM therapies, but 
the deletions that render these oHSV-1 incapable of replicating in normal tissue also 
compromise their lytic activity in tumor cells. Consequently, these viruses fail to  vf3 eradicate 
the tumor.  
In this study, I developed a new oHSV-1, named ICP4-miR124t, whose selective replication 
in GBM cells does not rely on defective genes, but rather is mediated by micro (mi)RNAs 
differentially expressed between normal tissue and GBM. MiRNAs recognize complementary 
target sequences in mRNAs resulting in repression of the mRNA. MiR124 is one of the most 
abundant miRNAs in developing and mature neurons, but is absent in GBM since its presence 
is incompatible with the tumor phenotype and viability. After introducing four tandem copies of 
the miR124 target sequence in the 3’UTR of the HSV-1 essential ICP4 gene, I observed robust 
replication of the resulting ICP4-miR124t oHSV-1 in primary glioblastoma cells, while viral 
growth was highly impaired in the same cells upon induction of mir124. Toxicity tests involving 
intracranial injection of immunocompetent and immunodeficient mice showed a dramatic 
reduction in vector toxicity compared to unregulated control virus. Moreover, ICP4-miR124t-
injected animals showed a loss of viral DNA in the brain over time, whereas an increase was 
observed in control virus injected animals. 
In conclusion the ICP4-miR124t oHSV-1 developed in this study is promising for GBM 
treatment because it is capable of killing miR124-negative tumor cells as efficiently as wild-type 
HSV-1, while lacking toxicity for normal brain. These results are of major Public Health 
importance not only as a potentially more effective alternative to current inefficient GBM 
treatments, but also as a new paradigm to treat other kinds of tumors by taking advantage of the 
differential miRNA expression between tumor and normal tissue. 
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1 INTRODUCTION 
 
 
 
1.1 Glioblastoma Multiforme (GBM) is the most malignant form of brain tumor without 
available effective treatment 
 
Glioblastoma Multiforme corresponds to the worst grade in Glioma classification according to 
the World Health Organization (WHO grade IV). The classification includes all tumors arising 
from the glial lineage in the brain and divides them into four grades (I-IV) depending on tumor 
phenotype, clinical behavior and prognosis. GBM is defined as an infiltrating glioma, biologically 
aggressive and resistant to therapy, characterized by the presence of tumor cell necrosis and/or 
angiogenesis, cytological atypia and mitotic activity 1 2,3.  
GBM is the most common form of astrocytoma in the adult population, accounting for 50-
60% of all gliomas and 2% of all human tumors, with an incidence in the US of 4-5 cases per 
100,000 persons per year. GBM incidence is higher in males and increases both with exposure 
to ionizing radiation and with age (from 0.2 cases per 100,000 persons per year in people below 
14 years of age to 4-8 cases per 100,000 persons per year in people above 45 years of age), 
making these three variables the main GBM risk factors. GBM is a sporadic tumor, but its 
incidence is increased in familial cancer syndromes, especially in Li-Fraumeni syndrome 
characterized by loss of functional p53, a tumor suppressor protein 1,2,4.  
GBMs have traditionally been sub-classified into two distinct types based on genotypic and 
phenotypic differences (Table 1). The first and most common type (>90% of GBM patients) 
includes primary tumors arisen de novo with no evidence of pre-existing lower grade glioma, 
typically diagnosed in older patients. 70% of primary GBM are characterized by loss of 
heterozygosity (LOH) of the long arm of chromosome 10, 36% show amplification of EGFR or 
its EGFRvIII tumor variant and 25% show mutation of PTEN. The second type includes 
secondary tumors derived from a lower grade astrocytoma, more often found in younger 
patients. Most secondary GBM present mutations of TP53 (65%) and overexpression of both 
PDGF and its receptor 1. Despite their genotypic differences, both GBM classes show a 
common miRNA expression pattern that is completely different from the one found in normal 
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brain, characterized among others by miR21, miR17 and miR10 overexpression and of miR124, 
miR137, and miR128 downregulation 5 
 
 
Table 1: Conventional GBM classification. 
 
 
 
A different, more accurate and more recent (2008) GBM classification is based on the 
molecular heterogeneity associated with human gliomas and divides GBM in four molecular 
sub-types, Mesenchymal, Proneural, Classical and Neural, based on the genomic abnormalities 
identified by the Cancer Genome Atlas Research Network (TGCA) on 206 GBM patient samples 
(Table 2) 6. The Mesenchymal subtype is characterized by either hemizygous deletions of the 
17q11.2 region containing NF1, or mutations in the NF1 gene and by chromosome 7p 
amplification associated with over-expression of EGFR and EGFRvIII tumor variant. The 
Proneural subtype molecular signature includes TP53 mutation (or LOH) together with 
amplification of PDGFRA on 4q12, point mutations of IDH1 and alterations of PDGF. Most of 
secondary GBM belong to this subtype. The Classical subtype presents chromosome 10q loss 
including the PTEN gene, chromosome 7p amplification associated with over-expression of 
EGFR and EGFRvIII, and 9p21 deletions containing CDKN2A and CDKN2B genes. The Neural 
subtype is associated with the expression of neuronal markers like NEFL, GABRA1, SYT1 and 
SLC12A5 and chromosome 7p amplification associated with over-expression of EGFR and 
EGFRvIII. Interestingly, by comparing the expression profiles of these four molecular GBM 
subtypes with normal brain transcriptome data, it appears that each subtype is derived from a 
different neural cell type, with the Classical group being similar to astrocytes, the Proneural 
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group to oligodendrocytes, the Mesenchymal group to astroglia and the Neural group to 
neurons. Moreover, there seems to be a correlation between a specific molecular subtype and 
its response to standard GBM treatment, with the Classical group having the best outcome and 
the Proneural group the worst6. 
  
 
 
Table 2: Novel molecular-based GBM classification.  
 
 
 
The four sub-types of GBM show different genotypic alterations, but the same miRNA expression signature, including 
miR124 down-regulation. 
 
 
Currently there are no effective therapies for GBM. The prognosis for patients diagnosed 
with the disease is usually very poor with an average survival of only 14 months after standard 
therapy. The standard therapy for GBM includes three steps that typically increase the lifespan 
of the patient by only of few months and have multiple side effects. First is surgery to remove as 
much as possible of the tumor mass and to provide diagnostic certainty. Second is radiotherapy 
to kill tumor cells through induction of DNA damage and apoptosis. Localized radiotherapy on 
the tumor bed has proven useful in increasing the lifespan of GBM patients without major 
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cognitive complications. Third is chemotherapy is but the blood brain barrier (BBB) limits the 
number of compounds that can reach the brain. BCNU (1,3,bis(chloroethyl)-1 nitrosurea), 
Temozolomide (alkylating agent) and bevacizumab (an artificial antibody against VEGF) are 
currently used to treat GBM patients after surgery, in association with radiotherapy 2. 
The limitations of the current GBM therapies clearly illustrate the need for a novel strategy to 
combat this very aggressive tumor. Oncolytic viruses represent a promising new approach to 
cancer therapy to be used alone or in combination with existing procedures. 
 
1.2 Herpes Simplex Virus Type-1 (HSV-1) based Oncolytic Viruses (OVs) are a 
promising but still ineffective therapy against GBM 
 
Oncolytic vectors (OVs) are attenuated lytic viruses designed to specifically replicate in tumor 
cells without affecting the surrounding normal tissue 7. Herpes Simplex Virus Type-1 (HSV-1) is 
an attractive platform for the development of a GBM-specific OV because of its neurotropism, 
high efficiency of infection, and its ability to rapidly replicate in infected cells. HSV-1 infectivity is 
much higher than that of other viruses used to generate OVs in that a 1:1 ratio of the number of 
HSV-1 viral particles and the number of target cells is sufficient to infect 100% of the cells. 
Infectivity is much lower in the case of Vesicular Stomatitis Virus (VSV), which requires a ratio of 
1:5000 between the number of host cells and viral particles to achieve efficient infection, or in 
the case of Adenovirus (AdV) where the effective ratio of cells to virus is 1:3000. Moreover, at 
least half of the very large, 152-kb genome of HSV-1 codes for functions that are not essential 
for viral propagation in vitro and can be deleted or modified without affecting the ability of the 
virus to quickly infect and spread. Lastly, several anti-herpetic drugs are readily available to 
keep oncolytic HSV (oHSV) replication under control in therapeutic applications 8. 
HSV-1 is a double-stranded DNA virus with a very wide host cell range. In many cells, once 
the virus enters, its lytic replication process begins, causing cell death and release of viral 
progeny as quickly as 10h after initial infection. The HSV-1 lytic cycle starts with the interaction 
between the viral essential glycoprotein gD and one of its receptors on the cell surface, followed 
by a signaling cascade that activates the two other essential glycoproteins gB and gH, both 
necessary to complete the fusion/entry process; the HSV-1 envelope and cell membrane fuse to 
allow entry of the viral DNA-containing capsid into the cytoplasm. To infect its target cell HSV-1 
can use several different common receptors, including HVEM (HveA), Nectin-1 (HveC) and 3-O-
sulfated heparan-sulfate 9,10. Virtually all cells express at least one of these receptors, 
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accounting for the broad host range of the virus. Upon entry into the cell, capsids inject the viral 
DNA into the nucleus where the replication process takes place. Newly synthesized viral DNA is 
assembled into new viral capsids in the nucleus, and then the DNA-containing capsids acquire 
new envelopes by nuclear membrane budding and further processing through the Golgi 
apparatus. The mature virus finally exits into the extracellular space by lysis of the infected 
cell 11-13. Only in sensory neurons HSV-1 can establish a latent state, characterized by silencing 
of lytic genes, expression of latency-specific RNAs (LATs) and persistence of the viral genome 
as an episome with no risk of insertional mutagenesis of the host genome. The HSV-1 genome 
is organized into a Unique Long (UL) and a Unique Short (US) region, each flanked by inverted 
repeats (Figure 1) 11,14,15. The junction between the internal repeats is called the joint and 
contains one copy of the ICP0, ICP4 and γ34.5 genes.  
 
 
 
 
Figure 1: Organization of the HSV-1 genome.  
The 152-kb HSV-1 genome is organized into a Unique Long (UL) and a Unique Short (US) regions, each flanked by 
inverted repeats, terminal (TR) and internal (IR). The region between UL and US, called the joint, consists of the two 
internal repeats and contains one copy each of the LAT, ICP0, ICP4 and γ34.5 genes. The unique regions can flip 
back and forth, creating four possible HSV isomers. Here is depicted the isomer conventionally used to represent the 
HSV-1 genome. All most relevant genes for this study are depicted. 
 
 
The unique regions can flip back and forth, creating four possible HSV isomers and making 
the HSV genome unstable and prone to internal recombination 16. The viral genome codes for at 
least 84 proteins plus several untranslated transcripts. Its genes are expressed in a temporal 
cascade in which the five immediate early (α) genes that code for regulatory proteins (ICP0, 
ICP4, ICP27, ICP22, ICP47) are expressed first and drive the expression of early (β) genes, 
necessary for DNA replication, and late (γ) genes that code for structural proteins assembled 
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into viral particles. HSV-1 genes are also classified into essential and non-essential based on 
their requirement for viral growth in vitro. Only half of HSV-1 genes are absolutely necessary for 
viral reproduction both in vitro and in vivo. The remaining genes are mainly involved in virus-
host interactions that allow the virus to overcome the natural defenses of the cell against 
infection in vivo 11,15. 
One of the most common designs to create a tumor-specific oHSV takes advantage of the 
deletion of one or more of the non-essential genes that HSV-1 uses to block the cell’s natural 
antiviral defenses. The result of the deletion is a replication-impaired vector that grows very 
poorly in normal cells but can replicate efficiently in cancer cells where these antiviral pathways 
are impaired or non-functional. Two different conditionally replication-defective oHSVs named 
HSV1716 and G207 have been tested in clinical trials on GBM patients while a third, named 
OncoVEX, is undergoing clinical trials on melanoma patients and a fourth, named NV1020, has 
been tested in clinical trials on metastatic colorectal cancer (CRC) patients (Table 3). Each of 
these has been shown to be safe for patients but evidence of anti-tumor efficacy has been 
sporadic 2-4,17. 
 
 
Table 3: oHSV-1 in clinical trials. 
 
 
 
Four replication-compromised oHSV-1 have been tested in clinical trials, the first two on GBM patients. All 
demonstrated to be safe for patients, but too attenuated to effectively overcome the tumor.  
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HSV1716 carries deletions of the RL-1 gene encoding the γ34.5 protein. This protein is 
normally expressed by the virus to overcome the activity of PKR, a kinase that is induced by the 
cells in response to infection or other forms of stress. Activated PKR phosphorylates the α 
subunit of the eIF2 translation initiation factor (eIF-2α), causing a complete block of protein 
synthesis. Viral γ34.5 works by activating PP1 phosphatase, that in turn dephosphorylates eIF-
2α and restarts protein synthesis necessary for the virus to complete its lytic cycle. A virus 
deleted for γ34.5 cannot replicate in normal cells, but only in cells where the PKR pathway is 
compromised and non-functional, such as in tumor cells that typically exhibit constitutive 
activation of the PKR-inhibiting EGFR/Ras/MEK pathway. HSV1716 showed promising results 
in phase I-III clinical trials. Up to 105 infectious units were injected in 12 patients bearing either 
newly diagnosed or recurrent high grade malignant glioma and were well tolerated, exhibiting no 
sign of toxicity in the normal tissue surrounding the tumor and showing some evidence of 
efficacy by increasing the life span of a few patients (respectively 15, 18 and 22 months of life 
after GBM diagnosis, in three patients) when combined with classical chemo- and radiotherapy 
after tumor surgery. However, tumor eradication was not observed and none of the patients 
were cured 2,4,18-20. 
G207 is a doubly attenuated vector created to increase tumor specificity and safety for the 
normal brain by deleting the UL39 viral gene in addition to both copies of RL-1. UL39 encodes 
the ICP6 protein, the viral counterpart of the large subunit of mammalian ribonucleotide 
reductase (RR), an enzyme required for the de-novo synthesis of dNTPs essential for DNA 
replication. The virus requires ICP6 to infect post-mitotic cells like neurons, where DNA is not 
replicated and cellular RR is not expressed. In the absence of ICP6 the virus can only infect 
mitotic cells, such as cancer cells where RR is usually overexpressed because of the 
constitutive activation of the Rb/p16/EF2 pathway. Thus a virus deleted for both γ34.5 and ICP6 
will grow only in cells that do not express PKR but overexpress RR, a common phenotype of 
GBM cells but not of normal cells 21. G207 has been tested in primates in preclinical studies and 
in phase I studies on patients with grade IV GBM. The vector was shown to be safe for patients 
at doses as high as 109 infectious particles, much higher than those used with HSV1716 21. 
However, anti-tumor efficacy studies performed by intra-tumor injection of G207 into highly 
invasive GBM xenografts derived from patient biopsies showed that despite some anti-tumoral 
effect, specifically a reduction in tumor volume, G207 did not significantly improve animal 
survival compared to other treatments, indicating that this oHSV had no clinical efficacy by 
itself.22,23 
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OncoVEX is a oHSV recently entered into clinical trials for melanoma. It is a doubly 
attenuated virus that carries deletions of both γ34.5 and ICP47 along with insertion of a GM-
CSF expression cassette. GM-CSF is an immunostimulatory molecule whose expression 
enhances the tumor-specific immune response against tumor antigens released after lytic 
replication of the virus, as demonstrated in mouse models. This vector has completed a Phase 
II clinical study where it was injected into accessible melanoma lesions, resulting in the 
regression of the injected lesions as a direct oncolytic effect and in the regression of the non-
injected lesions as a secondary immune-mediated antitumor effect in 28% of treated patients. A 
Phase III clinical trial on patients with grades III and IV unresectable melanoma has recently 
started 2,3,24 
NV1020 is an attenuated, joint-deleted oHSV vector with only one copy of the ICP0, ICP4 
and γ34.5 genes normally present in two copies in the HSV1 genome. The vector also carries 
deletions of the UL24 and UL56 non-essential genes and expresses the TK gene with 
immediate-early kinetics from the ICP4 promoter. This set of mutations makes the virus very 
attenuated and able to grow only in malignant cells that can complement the activities of the 
deleted viral genes, but not in normal quiescent cells 25. NV1020 has completed Phase I and II 
clinical trials on patients with refractory metastatic colorectal cancer (mCRC) of the liver 26. The 
virus was shown to be safe for the patients at a concentration of up to 1x108 infectious units 
without major adverse effects and demonstrated some effectiveness in reducing tumor size after 
chemotherapy and in increasing the median survival of the treated patients. A Phase III clinical 
trial for this virus has been proposed 17. 
Despite being safe for patients and showing some tumor killing ability, the oHSV tested so 
far in clinical trials are too attenuated to efficiently replicate in GBM and eradicate the tumor in 
the gaffected patients. To obtain a more effective oHSV that can grow and efficiently kill only 
tumor cells without affecting the surrounding normal tissue, I created a different kind of vector 
that is not deleted for any of its genes, but in which the expression of ICP4, one of its essential 
genes, is controlled by miR124, a neuronal-specific miRNA that is highly expressed in normal 
brain but not in GBM.  
 
1.3 MiR124 absence is specific for GBM cells 
Micro (mi)RNAs, short ∼21-23 nucleotide-long non-coding RNAs, are key regulators of almost 
every cellular pathway in protozoa, metazoa and plants that function by post-transcriptionally 
repressing gene expression at the mRNA level.  
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Figure 2: MicroRNAs biosynthesis.  
MiRNAs are short ∼21-23 nucleotide-long non-coding RNAs that function by post-transcriptionally repressing gene 
expression at the mRNA level. MiRNAs work in the form of miRISCs, ribonucleoprotein complexes comprised of the 
guide miRNA strand and several proteins of which AGOs and GW182 are the best-known components. In animals, 
the main mechanism of interaction between miRNA loaded on the miRISC and its target mRNA involves inexact 
base-pairing between the two molecules. After recognition of its target mRNA, the miRISC works either by directly 
inhibiting mRNA translation or by inducing mRNA deadenylation and consequent degradation. Another mechanism of 
miRNA-mediated mRNA silencing typical of plants but very rare in animals involves exact base-pairing between the 
entire miRNA and the 3’UTR of its target mRNA that induces mRNA degradation through an endonucleolytic 
mechanism typical of RNAi. 
 
 
MiRNAs work in the form of miRISCs (Figure 2), ribonucleoprotein complexes comprised of 
the guide miRNA strand and several proteins of which AGOs and GW182 (glycine-tryptophan 
protein of 182 kd) are the best-known components 27,28. In animals, the main mechanism of 
interaction between miRNA loaded on the miRISC and its target mRNA involves inexact base-
pairing between the two molecules. In fact, the only requirement for an miRNA to work is perfect 
homology between its seed sequence, the nucleotide stretch between positions 2 and 8, and a 
complementary region usually in the 3’UTR of the target mRNA 29. This characteristic not only 
allows for the regulation of multiple mRNAs by a single miRNA, but also for the regulation of a 
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single mRNA by different miRNAs, fine-tuning cell gene expression and increasing the 
complexity of the system. After recognition of its target mRNA, the miRISC works either by 
directly inhibiting mRNA translation or by inducing mRNA deadenylation and consequent 
degradation. There is another mechanism of miRNA-mediated mRNA silencing that is typical of 
plants but occurs very rarely in animals. In this case, base-pairing between the miRNA and the 
3’UTR of its target mRNA is perfect along the entire 20-22 nucleotide length of the miRNA and 
induces mRNA degradation through an endonucleolytic mechanism typical of RNAi 30,31. 
According to the miRBase database, 1527 precursors and 1921 mature human miRNAs had 
been discovered by Nov 2011. Most of these miRNAs are expressed in a tissue-dependent and 
developmental stage-dependent manner, contributing to the diversity of protein expression in 
different organs and during different life stages. 
 
 
 
 
Figure 3: MiRNAs involved in the development of the Central Nervous System (CNS). 
During neuronal development, pluripotent embryonic stem cells (ESCs) gradually differentiate first into multipotent 
neural stem cells (NSCs), then into lineage-specific neuronal progenitors (NPCs), and then into mature neurons and 
glia (oligodendrocytes and astrocytes). This complex process occurs through a combination of internal and external 
signaling pathways in which miRNAs play an essential role. MiR124 is a key player in neurogenesis being gradually 
upregulated during neuronal differentiation. In the mature brain, miR124 is expressed in virtually all post-mitotic 
neurons but not in glial cells, NPCs or NSCs. 
 
 
MiR124 is the most abundant miRNA of the adult mammalian central nervous system 
(CNS), accounting for 25-48% of all miRNAs present in the brain 32. The CNS is composed 
primarily of neurons and glia. During neuronal development, pluripotent embryonic stem cells 
(ESCs) gradually differentiate first into multipotent neural stem cells (NSCs), then into lineage-
specific neuronal progenitors (NPCs), and then into mature neurons and glia. This complex 
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process occurs through a combination of internal and external signaling pathways in which 
miRNAs play an essential role 33. As illustrated in Figure 3, miR124 is a key player of 
neurogenesis being gradually upregulated during neuronal differentiation not only in humans but 
also in many other species from nematodes to zebrafishes to chicks to mice 34. The miR124 
stem loop sequence is, in fact, well conserved from nematodes to primates. In the mature brain, 
miR124 is expressed in virtually all post-mitotic neurons but not in glial cells, NPCs or 
NSCs 33,35-37. 
Several in vitro studies have shown that overexpression of miR124 in non-neuronal cells like 
HeLa cells 38 or ESCs 39 can induce a shift toward neuronal differentiation. Moreover, it has 
been reported that miR124 is directly involved in modulating the transition from NPCs to mature 
neurons. During this process the factor RE-1 Silencing Transcription Factor (REST), a negative 
regulator of mir124 gene expression, is gradually lost, inducing the upregulation of miR124. 
MiR124 in turn inhibits the expression of non-neuronal genes 40 like SCP1 (small C terminal 
phosphatase-1), a component of the REST transcription complex, SOX9 (SRY-box transcription 
factor), involved in glial cell specification by controlling glial-gene expression in the CNS, CDK6 
(cyclin dependent kinase-6), involved in the cell cycle G1/S transition, and PTBP1 
(polypyrimidine tract binding protein-1), an inhibitor of neuronal specific alternative splicing that 
allows the expression of neuronal genes to prevail 41,42. MiR124 is also important for 
determining the fate of CNS-cells other than neurons 43. It has been demonstrated that in a 
population of NPCs, miR124 overexpression decreases the rate of glial cell formation by 
reducing the amount of phosphorylated STAT3, a very important transducer of glial cell 
differentiation 44. Human miR124 is encoded by three genes located on three different 
chromosomes and found often epigenetically silenced through hypermethylation in several 
precancerous lesions and in different types of leukemia, lymphoma and brain, colon, breast and 
lung cancer 45,46. In particular, miR124 is significantly downregulated in anaplastic astrocytomas 
(AA WHO grade III) and Glioblastoma Multiforme (GBM WHO grade IV) relative to non-
neoplastic tissue, while being 8- to 20-times upregulated during differentiation of cultured mouse 
NSCs 37. Transfection of miR124 into mouse-derived NSCs and mouse and human-derived 
GBM primary cells has been shown to induce morphological changes consistent with neuronal 
differentiation. Transfection of miR124 into GBM cell lines U251 and U87 has been shown to 
induce neuronal differentiation through cell cycle arrest in G1, associated with the 
downregulation of CDK6 and pRB, both substrates of miR124 post-transcriptional silencing, 
meaning that expression of miR124 in GBM is incompatible with maintenance of the tumor 
phenotype and viability 42,43. 
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The lack of current effective therapies for Glioblastoma Multiforme indicates an urgent need 
for innovative approaches to fight this very aggressive cancer. While existing HSV-based 
replication-impaired OVs have been shown in clinical trials to be safe for GBM patients at 
relatively high doses, they are not sufficiently effective to offer a significant benefit to the 
affected patients. In this study I describe the creation of a novel miR124-regulated replication-
competent oncolytic vector called ICP4-miR124t that is able to specifically kill GBM cells without 
affecting the surrounding normal tissue by taking advantage of the consistent tumor-specific 
downregulation of miR124 compared to normal brain. An attractive aspect of this strategy is that 
GBM cells cannot up-regulate miR124, causing resistance to the virus, without losing their 
malignant phenotype and viability 43, thus excluding the possibility of tumor-cell escape from the 
treatment. In addition, unlike the existing oHSVs, ICP4-miR124t maintains the full complement 
of viral genes and is therefore able to grow like an unregulated virus in permissive cells that lack 
miR124. The results of this study indicate that ICP4-miR124t is indeed both selective for the 
tumor where it maintains its full replication efficiency and non-toxic when injected at high doses 
into the brains of healthy mice where its replication is repressed. Thus a miR124-controlled 
oHSV could potentially be a safe and effective therapeutic tool against GBM. 
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2 METHODS 
 
 
 
2.1 Cell lines 
 
All cells utilized in this study were maintained at 37°C with 5% CO2 
 
Vero African Green Monkey Kidney (CCL-81), U2OS Human Osteosarcoma (HTB-96), 
HEK 293T/17 Human Epithelial Kidney (CRL-11268) and U87 Human Grade IV Glioblastoma 
immortalized adherent cell lines were purchased from ATCC (Manassas, VA) and grown in 
Dulbecco’s Modified Minimum Essential Medium (DMEM, HyClone) with 10% Fetal Bovine 
Serum (FBS, Sigma), 2 mM L-glutamine (Cellgro), 100 U/mL Penicillin (Cellgro), and 100 
μg/ml Streptomycin (Cellgro).  
SHSY5Y Human Neuroblastoma-derived immortalized adherent cells, generously donated 
by E.A. Chiocca (Ohio State University), were grown in 1:1 mixture of MEM and F12 medium 
with 10% FBS (Sigma), 0.1 mM Nonessential amino acids (NEAA, Cellgro), 100 U/mL 
Penicillin (Cellgro), and 100 μg/ml Streptomycin (Cellgro). 
50B11 (Rat-Dorsal Root Ganglia-derived) immortalized adherent cells, generously donated 
by Dr A. Hoke (Johns Hopkins University, Baltimore, MD, USA) 47, were grown in Neurobasal 
medium (Gibco) with 10% FBS (Sigma), 2% B27 supplement (Gibco), 20% glucose (Sigma), 1 
mg/ml blasticidin (Lonza), and 2 mM L-glutamine (Cellgro). To induce differentiation, cells 
were maintained in growth medium with 75 μM Forskolin (Sigma) for 24-48 h 47. 
PC12 (rat pheochromocytoma) cells were grown in DMEM (HyClone) plus 5% FBS (Sigma) 
and 10% Horse serum (HS), 2 mM L-glutamine (Cellgro), 100 U/mL Penicillin, 100 μg/ml 
streptomycin, Pen/Strep (Cellgro). To induce differentiation, cells were maintained in growth 
medium with 1% serum and 50 ng of 2.5s Nerve Growth Factor (NGF) (Sigma) until cells 
showed neuronal-like phenotype 48. 
GBM30 and Gli68 patient-derived primary glioma spheroids lines, generously donated by 
E.A. Chiocca (Ohio State University), were grown in Neurobasal medium (Gibco) plus 2% B27 
w/o vitamin A, 2 mg/ml amphotericin (Lonza), 100 μg/ml gentamycin (Lonza), 2 mM L-glutamine 
(Cellgro), plus 10 ng/ml Recombinant Human Epidermal Growth Factor (EGF) (Shenandoah 
Biotechnology) and 10 ng/ml Human Recombinant Basic Fibroblast Growth Factor βFGF 
(Shenandoah Biotechnology).  
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2.2 HSV-1 infection on U2OS and VERO cells  
 
2.2.1 Infection to test viral growth 
 
Vero and U2OS cells were the two established immortalized adherent cell lines routinely used in 
our laboratory to test viral growth. The day before infection cells were plated as a 70% confluent 
monolayer. 24 h later 100% confluent wells were infected at an established multiplicity of 
infection (MOI) in serum free media and incubated at 37°C in 5% CO2. 2 h after the infection 
each well was overlaid with DMEM plus 10% FBS and maintained at 33°C in 5% CO2, a 
condition that does not interfere with viral growth but stops cells from becoming over-confluent 
in the plate. At different time-points after initial infection, viral supernatant was collected and 
titered to quantify viral yield.  
 
2.2.2 High scale viral production  
  
In order to have enough virus to perform both in vitro and in vivo experiments all viruses used in 
this study were grown to high titer on U2OS. 24 h before infection U2OS were plated as a 50% 
confluent monolayer on T150 tissue culture flasks (6 T150 flasks per virus). The day of infection, 
100% confluent U2OS were infected with a MOI=0.001 as previously illustrated (see section 
2.2.1). 72-96 h after infection, flasks were treated with 5 M NaCl solution to a final concentration 
of 0.45% to detach the virus from cell membranes and incubated for 30’ at RT while slowly 
shaking. Following Sodium-Chloride (NaCl) treatment both cells and supernatant were 
collected, sonicated using the Ultrasonic Processor XL sonicator (Misonix Inc.) to free the virus 
still trapped inside cells and then cleaned from cellular debris through centrifugation at 3000 
revolutions per minute (rpm) for 10’ followed by filtration through a 0.8 um Versapor filtering 
membrane (PALL Corporation). The clean viral supernatant was then concentrated by 19,000 
rpm centrifugation for 30-45’ and the viral pellet resuspended in the minimum possible volume 
of a 10% Glycerol solution in 1X Phosphate-Buffered-Saline (PBS) by slow overnight shaking at 
4°C. The resulting concentrated virus was divided in 10 ul aliquots and stored at -80°C. One 
aliquot was used for titration in U2OS as described in section 2.2.3.  
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2.2.3 Viral titration in plaques forming units (p.f.u  /ml) 
 
Titration of viral supernatant was performed through infection of a 48 well of either Vero or 
U2OS with serial 10-fold dilutions of viral supernatant. The day before infection cells were plated 
as a monolayer on a 48 well dish at a density of 0.8x105 cells/well for Vero and 1.5X105 
cells/well for U2OS. 24 h later cells were infected with serial 10-fold dilutions of each 
supernatant in 120 μl of serum-free media and incubated at 37°C in 5% CO2. 2 h after the 
infection each well was overlaid with 120 μl of growth media plus 5% methylcellulose and 
maintained at 33°C in 5% CO2. 72-96 h after infection methylcellulose containing supernatant 
was removed and plates were washed with PBS and incubated for 2 h at room-temperature 
(RT) in a crystal-violet solution (50% Methanol, 0.1% Crystal-Violet) to stain viral plaques. The 
staining solution was then removed and each well washed twice with water and allowed to dry. 
Live cells stained purple; dead cells from viral infection resulted in clear plaques that were 
counted with an inverted microscope. The titer results were then calculated in p.f.u /ml (plaque 
forming units per ml of viral preparation). Triplicates were used for statistical analysis. 
 
2.2.4 Viral titration in Viral Genome Copy Number calculated by qPCR  
 
In order to perform in vivo experiments, viral titers calculated in p.f.u /ml, as described in section 
2.2.3, were converted into gc /ml through qPCR. Two separated aliquots of virus prepared as 
described in section 2.2.2 were processed to extract viral DNA using DNAeasy Blood and 
Tissue Kit (QIAGEN) according to the manufacturer’s instructions. qPCR was performed using 
the StepOne Plus Real Time PCR System (Applied Biosystem) with customized primers (gD-F 
and gD-R from Applied Biosystems) and probe (FAM-TAMRA TaqMan Probe from Applied 
Biosystems) for the HSV glycoprotein D (gD) gene (see primer table). The values were then 
compared to the known number of copies of a pEntr-gD DNA plasmid present in a midi DNA 
plasmid preparation obtained using the DNAeasy Blood and Tissue Kit (QIAGEN) according to 
the manufacturer’s instructions The pEntr-gD construct had been previously created in the 
laboratory by cloning the entire gD gene between two EcoRI restriction sites in the pEntr1A 
vector (Invitrogen). Viral genome copies were quantified based on a standard curve calculated 
according to the manufacturer’s instructions by qPCR amplification of serial 10-fold dilutions of 
the pEntr-gD plasmid of known concentration (Standard Curve Method from Applied 
Biosystems). 
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2.3 Polymerase Chain Reaction  
 
 
Table 4: PCR primers used. 
 
 Primer F Primer R 
gD qPCR customized primers to 
quantify oHSV genome copy number 
(Section 2.2.4) 
gD-Fwr 
5’CCCCGCTGGAACTACTATGACA3’ 
gD-Rev 
5’GCATCAGGAACCCCAGGTT3’ 
gD qPCR customized TAMRA 
probe  (Section 2.2.4) 
gD-Probe 
TTCAGCGCCGTCAGCGAGGA 
 
5’ Phosphorylated  oligos to 
generate pLuc-124T construct 
(Section 2.4) 
T124-F: 
5’PactagtGGCATTCACCGCGTGCC
TTAtagtaccagGGCATTCACCGCGTGCCT
TAaggatcctGGCATTCACCGCGTGCCTTA
atgactgcGGCATTCACCGCGTGCCTTAga
gct3’  
T124-R: 
5’agctcTAAGGCACGCGGTGAATGCC
gcagtcatTAAGGCACGCGGTGAATGCCagga
tcctTAAGGCACGCGGTGAATGCCctggtacta
TAAGGCACGCGGTGAATGCCactagt3’ 
5’ Phosphorylated  oligos to 
generate pLuc-Con construct 
(Section  2.5) 
Tcon-F: 
5’PactagtATCGAATAGTCTGACTAC
AACTtagtaccagATCGAATAGTCTGACTA
CAACTaggatcctATCGAATAGTCTGACTA
CAACTatgactgcATCGAATAGTCTGACTA
CAACTctcgagct3’  
Tcon-R: 
5’agctcgagAGTTGTAGTCAGACTATT
CGATgcagtcatAGTTGTAGTCAGACTATTCG
ATaggatcctAGTTGTAGTCAGACTATTCGAT
ctggtactaAGTTGTAGTCAGACTATTCGATac
tagt3’ 
Amplification of CS cassette to 
target gC (Section 2.7.1) 
gC-CS F:  
5’gcaatcgtgtacgtcgtccgcacatcacagtcg
cggcagcgtcatcggcggGGCCTGGTGATGAT
GGCGGGATCG3’ 
gC-CS R:  
5’gagggggaccaaactatatagatattaaaaaggt
aacgggggggtctcgcgTCAGAAGAACTCGTCA
AGAAGGCG3’ 
Diagnostic PCR to check CS 
cassette insertion and excision in gC 
(Section 2.7.1) 
gC F:  
5’atgacgtggcaccgcgactcc 3’ 
 
gC R:  
5’cgcggcaatgatcacaactccc3’ 
 
Amplification of eGFP with T2A 
( Section 2.7.1) 
T2A-eGFP-F: 
5’GAGGGCAGAGGAAGTCTGCTAA
CATGCGGTGACGTCGAGGAGAATCCT
GGCCCAatggtgagcaagggcgagga3’ 
gC-eGFP-R : 
5’gagggggaccaaactatatagatattaaaaaggt
aacgggggggtctcgcgTTACTTGTACAGCTCGT
CC3’ 
Amplification of T2-eGFP to 
target gC (Section 2.7.1) 
gC-T2A-F: 
5’gcaatcgtgtacgtcgtccgcacatcacagtcgcggc
agcgtcatcggcggGAGGGCAGAGGAAGTC
TG CTA3’ 
gC-eGFP-R: 
5’gagggggaccaaactatatagatattaaaaaggtaacg
ggggggtctcgcgTTACTTGTACAGCTCGTCC3’ 
 Primer F Primer R 
5’ Phosphorylated oligos to 
generate ICP4-4xT124-ISceI-Kan-
pEntr1A construct (Section 2.7.2.1 
step 1) 
ICP4 Oligo F:  
5’Paagttgtggactgggaaggcgcctgggac
GAAGACGACGGCGGCGTTCGA3’ 
ICP4 Oligo R: 
5’PaattACTAGTttacagcaccccgtcccccTC
GAACGCGCCGCCGTCGTCTTC3’ 
Amplification of pL-124-ICP4 to ICP4-F:  
5’aagttgtggactgggaaggcgcctgggacG
ICP4-R:  
5’gctactgcaaaacttaatcaggttgttgccgttattg
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DNA fragments for subcloning were amplified by Polymerase Chain Reaction (PCR) using 
either High Fidelity Accuprime PFX DNA Polymerase (Invitrogen) or High Fidelity Accuprime GC-
rich DNA Polymerase (Invitrogen). Routine analytical PCR for detection of an amplification 
product or estimation of a product size was performed using Go-Taq (Promega) according to the 
manufacturer’s instructions. Listed in table 4 are the PCR primers utilized to generate the different 
constructs. 
 
2.4 Cloning techniques 
 
Listed in table 5 all the constructs described in this study. 
 
 
include ICP4polyA after 4x124 
element (Section 2.7.2.1 step 4) 
AAGACGACGGCGGCGTTCGA3’ cgtcttcgggtcGAGCTCAAGGCACGCGGTGA
ATGCCGCAG3’  
Amplification of I-SceI-kan 
selection cassette to insert flanking 
direct repeats Section 2.7.2.1 step 7) 
I-SceI-Kan-F: 
51taatGAGCTCtaatGCGGCCGCtaatATCT
ATGTCGGGTGCGGAGAAAGAGGtaatga
aatggcaaggatgcgacgaTAAGTAGGGATAA
CAGGGTAA3’  
I-SceI-Kan-R: 
5’taatGAGCTCtaatGCGGCCGCtaatTGCCAT
TTCATTACCTCTTTCTCCGCACCCCGACA
TAGATcaaccaattaaccaattctgattag3’ 
Amplification of 4xT124 cassette 
to target ICP4 (Section 2.7.3) 
ICP4-F: 
5’aagttgtggactgggaaggcgcctgggacgaagac
gacggcggcgttcga3’ 
ICP4-R: 
5’gctactgcaaaacttaatcaggttgttgccgTTTATTgc
gtcttcgggtc3’ 
Diagnostic PCR  to check for 
correct Cre-mediated excision of the 
BAC (Section 2.7.5) 
UL37-F:  
5’CAATAGGCGCTGCATAGGTC 3’ 
UL38-R:  
5’TTCATTGCGACCCCAGAT3’  
Amplification of rtTA gene from   
pgk-rtTA-Sv40polyA (Section 2.8.2 
step 1) 
BrtTA-F:  
5’GAAGATCTatgtctagactggacaagag
caaa 3’ 
NrtTA-R:  
5’GCGGCCGCAAttacccggggagcatgtca
agg3’ 
Amplification of Human Pri-
miR124 from U87 total DNA (section 
2.8.2 step 2) 
BmiR124-F:  
5’tcgaGGATCCtgtcagtgcgcacgcacac 
3’ 
NmiR124-R:  
5’tgcaGCTAGCcagacccctcccctcgc3’ 
Amplification of Puro gene from 
pCDH-CMV-EF1 (Section 2.9.1 step 
1) 
X-Puro-F: 
5’atatatTCTAGAatgaccgagtacaagcccac3’ 
XS-Puro-R: 
5’tatatatatatctagaggtaccgtcgactcaggcaccgggt
tg3’ 
Amplification of pri-miR137 from 
U87 total DNA (section 2.9.2) 
NmiR137-F:  
5’tcgaggatccAAACACCCGAGGAAA
TGAAAAG3’ 
BmiR137-R:  
5’tcgagctagcGCTCAGCGAGCAGCAA
GAGTTC3’ 
Table 4: continued 
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Table 5: DNA constructs generated in this study. 
 
 
pLuc-T124 (Section 
2.5) 
 
pLuc-Tcon (Section 
2.5) 
 
KB (Section 2.7) 
 
KBJ (Section 2.7) 
 
KBBJ (Section 2.7) 
 
KBBJ-R (Section 2.7.1 
) 
 
gC-cs R (Section 2.7.1 
)  
KBBJ-gC-cs R (Section 
2.7.1 )  
T2A-eGFP R (Section 
2.7.1 )  
gC-T2A-eGFP R 
(Section 2.7.1 )  
KBG (Section 2.7.1 ) 
 
pEntr-ICP4-T124-kan 
(Section 2.7.2.1)  
KBG-R (Section 
2.7.2.2)  
KBG-ICP4-miR124t-
kan plus pRed/ET and pBad 
(Section 2.7.2.2) 
 
ICP4-miR124t-BAC 
(Section 2.7.2.2)  
KG (BAC removed-
Section 2.7.5)  
4xT124Luciferase
fLuc
CMV SV40polyA
fLuc
4xTConLuciferase
fLuc
CMV SV40polyA
fLuc
UL
BAC gC
UsgB ICP4Joint
UL
BAC gC
UsgB ICP4ΔJoint
UL
BAC gC
UsgB:
NT ICP4ΔJoint
UL
BAC gC
UsgB:
NT ICP4ΔJoint + Red/ET
Kan/ 
Strep
gC 3’UTRgC 3’ORF
+
UL
BAC
UsgB:
NT ICP4ΔJointgC
Kan/
strep
Red
/ET
eGFPT2A gC3’UTR
eGFPT2A gC3’UTR
UL
BAC
UsgB:
NT ICP4ΔJoint
gC-T2A-
eGFP
I-SceI/KanR dr ICP4polyAdr4xT124ICP4 3’end
pEntr1A pEntr1A
UL
BAC
UsgB:
NT ICP4ΔJoint
gC-T2A-
eGFP + Red/ET
UL
BAC
UsgB:
NT
ICP4-
4xT124
ΔJoint
gC-T2A-
eGFP
Dr I-SceI/KanR Dr ICP4polyA
Red
/ET
pBad-
I-SceI
+
UL
BAC
UsgB:
NT ICP4-4xT124ΔJoint
gC-T2A-
eGFP Dr ICP4polyA
UL UsgB:
NT ICP4ΔJoint
gC-T2A-
eGFP
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ICP4-miR124t (BAC 
removed-Section 2.7.5)  
pEP-miR124 (Section 
2.8.2)  
TetO-miR124 (Section 
2.8.2)   
TetO-intron (Section 
2.8.2) 
 
pCDH-miR124 (Section 
2.9.1)  
pCDH-miR137A 
(Section 2.9.2)  
 
 
2.4.1 DNA restriction digest and purification from agarose gel 
 
Plasmids and PCR products were restriction-digested at 37°C for 1 h, run on a 1% agarose 
0.001% Ethidium Bromide (EtBr) gel, and gel purified using the QIAEXII Gel extraction kit 
(QIAGEN) according to manufacture’s instructions. 
 
2.4.2 Ligation of DNA fragments and transformation of competent bacteria 
 
Linearized vector backbones and DNA inserts were ligated together at a 1:7 backbone: insert 
ratio using T4 DNA ligase (NEB) according to manufacturer’s instructions and incubated at 16°C 
overnight.  
 
2.4.3 Transformation of competent bacteria cells 
 
Ligation products were transformed into DH10β competent bacteria (NEB) according to the 
manufacturer’s instructions, plated on Luria-Broth (LB) agar plates (1% NaCl, 1% Bacto-
Trypton, 0.5% Yeast-Extract, 0.02% NaOH, 1.5% agar) containing the appropriate selection 
drug and incubated overnight at 37°C. 
 
UL UsgB:
NT ICP4-4xT124ΔJoint
gC-T2A-
eGFP Dr ICP4polyA
EF1 Intron rPuro-SV40polyAIntron Pri-miR124 
peP-miRpeP-miR
Tet-O Intron rPuro-SV40polyA bGH polyA-rtTa-Pcmv Kan/neoIntron Pri-miR124 
dsRed2.1
Tet-O Intron rPuro-SV40polyA bGH polyA-rtTa-Pcmv Kan/neoIntron
dsRed2.1
EF1 Intron PuroIntron Hu-mir124-3
pCDH-miR124
SV40polyA Plenti genes
EF1 Intron PuroIntron Hu-mir137A
pCDH-miR137A
SV40polyA Plenti genes
Table 5: continued 
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2.4.4 DNA extraction for screening of transformed bacteria colonies 
 
Transformed bacteria colonies grown on agar plates were picked, expanded overnight in LB 
broth (1% NaCl, 1% Bacto-Trypton, 0.5% Yeast-Extract, 0.02% NaOH) plus the appropriate 
selection drug and processed to extract plasmid DNA using the QIAprep Spin Miniprep Kit 
(QIAGEN) according the manufacturer’s instructions.  
 
2.5 Engineering of a firefly-Luciferase expression plasmid carrying the miR124 
responsive element, 4xTmiR124 
 
MiRBase (http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000443), a miRNA online 
database, was used to obtain the miR124 target sequence. The miR124-target utilized as a 
template was a miR124-perfect match to promote degradation of the target mRNA, instead of its 
translational inhibition. A miR124 responsive element (4xT124) was designed so that four 
copies of the 22- nucleotides (nt) long miR124 target sequence, each separated from the next 
by a different 7- or 8- nt random spacer were inserted into the 3’ untranslated region (UTR) of 
the luciferase reporter gene in a firefly-Luciferase (fLuc) expression plasmid (pMIR-Report 
Luciferase-Promega) as shown in Figure 4. The resulting plasmid was called pLuc-T124. This 
design has been shown to maximize the effect of the miRNA on the fLuc target gene while 
minimizing the risk of internal recombination between target sequences 49-52. To be used as 
control, a similar construct called pLuc-Tcon was created using a tandem of four copies of a 
random miR target sequence (Tcon) that didn’t respond to miR124 (Figure 4). To generate 
pLuc-T124 and pLuc-Tcon constructs, both miR124 and Con responsive elements were 
designed and purchased as single-stranded 5’-phosphorylated DNA oligonucleotides (oligos) 
carrying a SpeI restriction site at the 5’ end and a SacI restriction site at the 3’ end. Each oligo 
was dissolved in water to a final concentration of 3 μg/μl. 1 μl of each oligo was added to 48 μl 
of annealing buffer (10 mM Tris pH 7.5-8.0, 50 mM NaCl, 1mM TE) and incubated at 95°C for 
4’, shifted to 70°C for 10’ and then shifted to room temperature (RT) for 30’ and stored at 4°C. 
The annealed oligos and pLuc expression plasmid were digested with SpeI and SacI (NEB, 
New England Biolabs) at 37°C for 1 h and gel purified. The linear pLuc backbone was then 
ligated to each of the annealed oligos and the ligation product was transformed into DH10β 
competent bacteria (NEB) and selected on LB Ampicillin (amp) (100 μg/ml) agar plates. Amp-
resistant colonies were finally screened for correct insertion of either 4xT124 or Tcon oligos by 
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diagnostic digestion with BamHI, a restriction site present in the inserted fragment. One positive 
clone was selected for both pLuc-T124 and pLuc-Tcon. Both construct are illustrated in table 4. 
 
 
 
 
Figure 4: Design of a miR124-controlled Luciferase construct.  
A tandem of four 20-nucleotides long miR124 target sequences, each separated from the next by a unique 8 
nucleotides spacer (4xT124) was inserted in the 3’UTR of the fLuc reporter gene to create the pLuc-T124 construct. 
Similarly, a control sequence (Tcon) designed using a random miR target sequence non-responsive to miR124 was 
inserted in the 3’UTR of the fLuc reporter gene to create the pLuc-Tcon control construct. 
 
 
2.6 Analysis of MiR124 activity on the 4xT124 response element 
 
To verify that the presence of miR124 effectively blocked luciferase activity in the pLuc-
4xmiR124t plasmid and not in the pLuc-Con control, U2OS and HEK293AD cells, which do not 
express miR124 according to the miRNA.org official website, were transfected with either a pre-
miR124 (Ambion AM17100) or a pre-miR21 (Ambion AM17120) as negative control using 
siPORT-NeoFX transfection agent (Ambion) according to the manufacturer’s instructions. 
Transfection of these synthetic ready-to use double stranded miRNA-mimics resulted in 
transient production of the desired miRNAs. 24 h post pre-miRNA transfection, the cells were 
co-transfected with a 1:1 combination of either pLuc-T124 + a renilla luciferase (rLuc) reporter 
plasmid (pRL-CMV, Promega) or pLuc-con + pRL-CMV using Lipofectamine 2000 transfection 
reagent (Invitrogen) according to the manifacturer’s instructions. 48 h after the second 
transfection, cells where collected, lysed using a 5X luciferase lysis reagent (Promega) and both 
 22 
 
Firefly and Renilla  luciferase activities in cell lysates were measured by injecting 100 μl of either 
Firefly or Renilla luciferase assay buffers (Promega) on 10 μl of total cell lysate using a single-
tube luminometer (AutoLumat LB953-EG&G Berthold). Luciferase values (measured on Firefly 
light units or Flu) were then normalized to Renilla values (measured on Renilla light units or 
Rlu). Each measurement was done in triplicate to obtain statistically significant results.  
 
2.7 Engineering of the HSV-1 Genome 
 
 
 
Figure 5: Organization of the KBBJ genome.  
The deletion of the joint freezes the HSV genome as one of its isomers with a flipped Us region compared to the 
isomer conventionally used to represent the HSV-1 genome. The complete deletion of the joint eliminates one copy 
each of the LAT, ICP0, ICP4 and γ34.5 genes plus the promoter of ICP47. However the deletion stabilizes the vector 
against internal recombination events and facilitates accurate engineering without affecting the virus ability to 
replicate and kill tumor cells in vitro. The region of insertion of the BAC between UL37 and UL38 is depicted as well 
as the enhancing gB:NT modification in UL27. 
 
 
To generate the ICP4-miR124t HSV vector, I engineered a modified version, called KBBJ 
(Figure 5) of a bacterial artificial chromosome (BAC) containing the HSV-1 genome from the 
strain KOS (KB), originally donated to our lab by Dr. D.A. Leib 53. As part of a BAC the HSV-1 
genome can autonomously replicate in bacteria, rendering site-specific manipulations easier 
than in the past. The BAC sequences were located between loxP recombination sites in the 
UL37/UL38 intergenic region of the HSV-1 genome and could therefore be excised by Cre 
recombinase 54,55 to eliminate potential negative effects of these sequences on viral replication. 
In addition to the BAC elements, the region between the two loxP sites contained a 
chloramphenicol-selection gene (CM) to select CM resistant bacteria during BAC modifications, 
and a lacZ reporter gene under control of the SV40 promoter that can be used as marker in 
eukaryotic cells to detect the presence of the BAC 35All changes to KB and its derivatives were 
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performed in DH10β competent bacteria (NEB) using either the Red/ET recombination protocol 
(Gene Bridges) or a pBad/I-SceI modification adapted in our laboratory from Tischer et al. 56. 
The KBBJ vector was previously created in the laboratory by modifying the original KB vector in 
two locations. KB was first engineered to carry a deletion in the internal repeat region (joint) 
between UL56 and US12. The deletion of the joint left one copy of each of the HSV-1 diploid 
ICP0, ICP4 and γ34.5 genes and deleted the promoter of ICP47, possibly interfering with ICP47 
gene expression However, the deletion of the joint also stabilized the vector against internal 
recombination events by freezing the HSV genome as one of its isomers. This modification 
greatly facilitated accurate engineering of the viral genome without affecting virus ability to 
replicate and kill tumor cells in vitro. 
 
 
 
Figure 6: Two steps Gene-Bridges Red/ET temperature-shift-mediated recombination in gC locus. 
Modification of gC using Gene-Bridges Red/ET recombination strategy showing the two steps of Red/ET 
temperature-shift-mediated recombination in the gC locus. In the first step a Kan-Strep-counter-selection cassette is 
introduced in front of the gC  stop codon. In the second step, the two selectable marker genes are substituted with a 
cassette containing the T2A-eGFP sequence of interest. The template containing the selectable genes is extended at 
both ends by PCR to add 50-bp regions of homology to the target region (homology arms). 
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Figure 7: pBad-I-SceI two steps modification of the Gene-Bridges Red/ET temperature-shift-mediated 
recombination in the ICP4 locus. 
In the first step, a DNA fragment containing the sequence of interest (ICP4 3’UTR containing 4xT124), a kanamycin 
(KanR) selection cassette flanked by direct repeats (dr) and an I-SceI restriction site is inserted into a specific region 
of the HSV-BAC by Red/ET recombinase. In the second step the selected BAC is transformed with a pBad/I-SceI 
plasmid that codes for the I-SceI restriction enzyme expressed following arabinose induction. Then the induced I-SceI 
enzyme cuts at its unique site in the Kan-resistant HSV-BAC construct facilitating the Red/ET-mediated 
recombination between the repeats flanking the Kan cassette, eliminating it from the BAC DNA. 
 
 
This joint-deleted vector (KBJ) was further modified to create the KBBJ backbone by 
introducing a double mutation in gB, D285N/A549T, (gB:NT). This mutation in the gB 
glycoprotein was discovered in my laboratory and recently published as enhancing viral entry 57. 
To generate the ICP4-miR124t-BAC I added two additional modifications to the KBBJ 
parental backbone. The first, illustrated in Figure 6, was the introduction of the enhanced green 
fluorescent protein (eGFP) gene in-frame with the late viral gC gene to be co-expressed from 
the native viral gC promoter and used as marker of viral growth and spread both in vitro and in 
vivo. The resulting vector was called KBG. 
The second, illustrated in Figure 7, was the insertion of the 4xT124 responsive element from 
the pLuc-T124 construct (section 2.4) into the 3’ UTR of the KBG ICP4 gene. The resulting 
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vector was called ICP4-miR124t. A list of all the BAC constructs schematics is illustrated in 
Table 5. 
 
2.7.1 Insertion of T2A-eGFP in gC 3’end 
 
The first modification of KBBJ consisted in the insertion of the enhanced green fluorescent 
protein (eGFP) gene in-frame with the late viral gC gene and separated by a 2A translation-
pause sequence (T2A) 58,59. As a result, the gC and eGFP genes were efficiently co-expressed 
from the native late viral gC promoter making eGFP expression a very useful marker of viral 
growth and spread for both in vitro and in vivo studies.  
The pRed/ET-mediated recombination used to create the backbone relies on the use of a 
pRed/ET plasmid that contains two λphage-derived red genes under the control of an L-
arabinose-inducible promoter and a tetracycline (tet) resistance gene. Protein expression from 
the red genes is induced by L-arabinose and mediates homologous recombination between the 
BAC and a linear targeting construct. To generate the targeting construct (gC-CS), a counter-
selection cassette template (CS) encoding resistance to kanamycin (kanR) and sensitivity to 
streptomycin (strepS) was extended at both ends by PCR to add 50 bp regions of homology 
(homology arms) to target the 3’ end of the gC gene (Figure 8A). The PCR reaction was 
performed using High Fidelity Accuprime Pfx DNA Polymerase (Invitrogen) according to the 
manufacturer’s instructions supplemented with 1 μl of the counter-selection cassette template 
(200 ng/μl) and 1 μl of each primer (gC-csF, gC-csR 10 pmol/μl). The cycling protocol used was 
the following: 95°C for 5’, 30 cycles x (95°C for 30’’, 59°C for 30’’, 68°C for 2’), 68°C for 10’, 4°C 
forever. The resulting 1.3-kb gC-CS PCR product shown in Figure 8A was gel-isolated using the 
QIAEXII Gel extraction kit (QIAGEN) according to manufacturer’s instructions, resuspended in 
double distilled water (ddH2O) and sent for sequencing to verify the integrity of the amplified 
sequence. To introduce the targeting construct (Figure 9A), DH10β bacteria carrying the KBBJ 
vector containing the CM-resistance gene in the BAC region, were electroporated with pRed/ET 
expression plasmid containing the tet-resistance gene. Specifically, 24 h before electroporation 
a single KBBJ overnight culture was inoculated in CM (15 μg/ml) containing LB medium and 
grown at 37°C while shaking at 220 rpm. On the day of the electroporation 30 µl of KBBJ 
overnight culture were inoculated into 1.4 ml of LB medium and incubated at 37°C for 2 hours 
while shaking at 220 rpm. Bacteria were then collected and prepared for electroporation by 
washing them three times with cold double distilled water (ddH2O) and by resuspending them in 
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20 μl of ddH2O. Bacteria were then electroporated with 1 μl of pRed/ET plasmid (20 μg/μl) using 
a Biorad GenePulserXcell electroporator (Voltage 1650 V, Capacitance 25 uF, Resistance 
150Ω, Cuvette 1 mm).   
 
 
 
 
Figure 8: PCR to amplify the counter-selection cassette (CS) with homology arms for gC 3’ end 
(A) Generation of gC-CS targeting construct. A counter-selection cassette template encoding resistance to 
kanamycin (kanR) and sensitivity to streptomycin (strepS) was extended at both ends by PCR to add 50 bp regions of 
homology (homology arms) to target the 3’ end of the gC gene. (B) Generation of the T2A fragment. The eGFP gene 
was first extended by PCR with a forward primer containing a T2A sequence (T2A-eGFP-F) and a reverse primer 
carrying the gC 3’UTR homology arm previously used to target gC (gC-eGFP-R). (C) Generation of a gC-T2A-eGFP 
targeting construct. The T2A-eGFP fragment was extended with a second round of PCR to add the same 50-bp 
homology arms previously used to target the 3’ end of the gC ORF with the CS-cassette. (D) Agarose gel of the 
targeting constructs. PCR products were gel-isolated and sent for sequencing to verify the integrity of the amplified 
sequence. 
 
 
After electroporation, cells were incubated at 30°C for 70’ while shaking at 220 rpm and 
finally plated on LB agar plates containing CM (15 μg/ml) and tet (3 μg/ml) and incubated at 
30°C overnight. Due to a temperature sensitive origin of replication, pRed/ET is lost if bacteria 
are grown at temperatures over 30°C. One pRed/ET positive colony was then randomly 
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selected to host the recombination reaction in the gC locus of KBBJ (KBBJ-R illustrated in Table 
5). gC-CS was then electroporated into KBBJ-R bacteria. 24 h before electroporation, KBBJ-R 
bacteria were inoculated in CM (15 μg/ml) + tet (3 μg/ml) containing LB media and grown 
overnight at 30°C while shaking at 220 rpm. On the day of the electroporation, 30 μl of KBBJ-R 
overnight culture were inoculated into 1.4 mL of LB medium and incubated at 30°C for 2 h with 
220 rpm shaking. KBBJ-R bacteria were then induced to express the recombination proteins 
from pRed/ET through incubation of the 1.4mL culture at 37°C with 0.35% of L-arabinose for 45’ 
with 220 rpm shaking. Bacteria were then collected and prepared for electroporation by washing 
them three times with ddH2O and by resuspending them in 20 μl of ddH2O. Bacteria were then 
electroporated with 5 μl of the gC-CS fragment using a Biorad GenePulserXcell electroporator 
(Voltage 1650 V, Capacitance 25 uF, Resistance 150 Ω, Cuvette 1 mm). Following 
electroporation bacteria were incubated at 37°C for 70’ with shaking to allow Red/ET-mediated 
recombination between the homology arm-flanked selection cassette and the HSV genome in 
front of the gC stop codon. Cells were finally plated on CM (15 μg/ml) + tet (3 μg/ml) +kan (15 
μg/ml) agar plates and incubated at 30°C to avoid loss of Red/ET plasmid. Eight kan-resistant 
recombinants were selected and checked for strep sensitivity by streaking them on a CM (15 
μg/ml) + strep (50 µg/ml) + kan (15 μg/ml) agar plates. Streptomycin sensitivity can indeed be 
easily lost during the cloning procedure but it is required to complete the Red/ET-mediated 
recombination. Five kan-resistant-strep-sensitive recombinants were selected and BAC–DNA 
extracted. The site-specific insertion of the counter-selection cassette was checked in these five 
isolates by diagnostic PCR using primers outside the region of insertion of the BAC genome as 
shown in Figure 9B. The diagnostic PCR reaction was performed using High Fidelity Accuprime 
Pfx DNA Polymerase (Invitrogen) according to manufacturer’s instructions supplemented with 2 
µl of each BAC-DNA miniprep template and 1µl of each primer (gC-F, gC-R 10 pmol/μl). The 
cycling protocol used was the following: 95°C for 5’, 30 cycles x (95°C for 30’’, 59°C for 30’’, 
68°C for 2’), 68°C for 10’, 4°C forever. All five isolates showed the expected 2.1-Kb PCR band 
indicating the insertion of the counter-selection cassette when compared to the 800-bp band 
amplified from the KBBJ parental backbone. All five isolates were then analyzed by FIGE (Field 
Inversion Gel Electrophoresis) and compared to the original KBBJ backbone after overnight 
digestion of 20 μl of each BAC-DNA miniprep template with either BglII or HindIII. As illustrate in 
Figure 9C, in both digests all 5 isolates showed the expected 1.3 Kb shift of the DNA band 
containing the site of insertion that went for 17.4-Kb to 18.7-Kb in BglII digest and from 8.7-Kb to 
10-Kb in the HindIII digest, while maintaining intact the remaining pattern of digestion. Two 
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isolates (KBBJ-CS-A and KBBJ-CS-C illustrated in Table 5) were chosen from the pool and 
used for the following recombination step. 
 
  
 
 
 
(A): Schematic of the site-specific insertion of the counter-selection cassette in gC. (B): Diagnostic PCR. Five kan-
resistant isolates were checked for correct insertion of the CS cassette by diagnostic PCR using primers outside the 
region of insertion into the BAC genome. All five isolates were positive showing the expected 1.3-Kb shift from 800-bp 
to 2.1-Kb due to insertion of the 1.3-Kb large CS cassette. (C): Diagnostic FIGE digest. All five isolates were analyzed 
by FIGE and compared to the original KBBJ backbone after overnight digestion with either BglII or HindIII. In both 
digests all 5 isolates showed the expected 1.3 Kb shift of the DNA band containing the site of insertion that went for 
17.4-Kb to 18.7-Kb in BglII digest and from 8.7-Kb to 10-Kb in the HindIII digest, without changes in other bands. 
 
 
The next step of the Red/ET temperature-shift-mediated recombination involved the 
substitution of the counter-selection cassette with a cassette containing the T2A-eGFP 
sequence flanked by the same homology arms used in step one to target the 3’ end of the gC 
gene (Figure 10A). Two consecutive PCR reactions were used to generate the T2A-eGFP 
cassette. The eGFP gene was first extended by PCR with an upper primer containing a T2A 
sequence (T2A-eGFP-F) and a lower primer carrying the 5’ gC homology arm previously used 
to target gC (gC-eGFP-R) as shown in table 4. The PCR reaction was performed using High 
Figure 9: 1st step: counter-selection (CS) cassette insertion in gC 3’UTR. 
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Fidelity Accuprime Pfx DNA Polymerase (Invitrogen) according to manufacturer’s instructions 
supplemented with 1 μl of the eGFP template (200 ng/μl) and 1 μl of each primer (T2A-eGFP-F, 
gC-eGFP-R 10 pmol/μl). The cycling protocol used was the following: 95°C for 5’, 30 cycles x 
(95°C for 30’’, 59°C for 30’’, 68°C for 2’), 68°C for 10’, 4°C forever. The resulting 800 bp T2A-
eGFP PCR product shown in Figure 8B was gel-isolated using the QIAEXII Gel extraction kit 
(QIAGEN) according to manufacturer’s instructions and extended with a second round of PCR 
to add the same 50 bp homology arms used in the first step to target the 3’ end of the gC gene. 
The PCR reaction was performed using High Fidelity Accuprime Pfx DNA Polymerase 
(Invitrogen) according to manufacturer’s instructions supplemented with 1 µl of the T2A-eGFP 
template (200 ng/μl) and 1 μl of each primer (gC-T2A-F and gC -eGFP-R 10 pmol/μl). The 
cycling protocol used was the following: 95°C for 5’, 30  cycles x (95°C for 30’’, 59°C for 30’’, 
68°C for 2’), 68°C for 10’, 4°C forever. The 870 bp gC-T2A-eGFP PCR product shown in Figure 
8C was gel-isolated using the QIAEXII Gel extraction kit (QIAGEN) according to manufacturer’s 
instructions and resuspended in ddH2O. The gC-T2A-eGFP fragment was then electroporated 
into KBBJ-CS-A and KBBJ-CS-C electrocompetent bacteria for Red/ET mediated recombination 
to substitute the counter-selection cassette with the T2A-eGFP gene in front of the gC stop 
codon. 
One day before electroporation KBBJ-CS-A and KBBJ-CS-C bacteria, still carrying the 
pRed/ET plasmid, were inoculated in CM (15 μg/ml)+ tet (3 μg/ml) + kan (15 μg/ml) LB media 
and grown overnight at 30°C with 220 rpm shaking. On the day of the electroporation 30 μl of 
KBBJ-CS-A and KBBJ-CS-C overnight cultures were inoculated into 1.4 mL of LB medium and 
incubated at 30°C for 2 h with 220 rpm shaking. KBBJ-CS-A and KBBJ-CS-C bacteria were 
then induced to express the recombination proteins from pRed/ET through incubation for 45’ at 
37°C with 0.35% of L-arabinose while shaking at 220 rpm. Bacteria were then collected and 
prepared for electroporation by washing them three times with ddH2O and by resuspending 
them in 20 µl of ddH2O. Bacteria were then electroporated with 5 μl of the gC-T2A-eGFP 
fragment using a Biorad GenePulserXcell electroporator (Voltage 1650 V, Capacitance 25 uF, 
Resistance 150 Ω, Cuvette 1 mm). Following electroporation, bacteria were incubated for 70’ at 
37°C with shaking to allow Red/ET mediated recombination between the homology arm-flanked 
selection cassette and the KBBJ-CS genome in front of the gC stop codon. Cells were finally 
plated on CM (15 μg/ml) + strep (50 μg/ml) agar plates and incubated at 37°C to allow loss of 
Red/ET plasmid. 18 Strep-resistant recombinants (9 derived from the KBB-CS-A and 9 from the 
KBBJ-CS-C) were selected and BAC DNA. The site-specific insertion of T2A-eGFP gene was 
checked on these 18 isolates by PCR using the gC-F and gC-R primers outside the region of 
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insertion of the BAC genome. The PCR reaction was performed using High Fidelity Accuprime 
Pfx DNA Polymerase (Invitrogen) according to manufacturer’s instructions supplemented with 
1μl of the BAC-DNA template (200 ng/μl) and 1μl of each primer (gC-F and gC-R 10 pmol/μl). 
The cycling protocol used was the following: 95°C for 5’, 30 cycles x (95°C for 30’’, 59°C for 30’’, 
68°C for 2’), 68°C for 10’, 4°C forever. The two isolates (KBBJ-T2A-eGFP-A6 and KBBJ-T2A-
eGFP-C9) that showed the expected 1.7-Kb PCR amplification band shown in the Figure 10B 
were then compared by FIGE to the original KBBJ and the KBBJ-CS-A and KBBJ-CS-C 
backbones after overnight digestion of 20 µl of each BAC-DNA template with either BglII or 
HindIII. 
 
 
 
 
(A): Schematic of the site-specific substitution of the CS- cassette in gC with a T2A-eGFP cassette. (B): Diagnostic 
PCR. The site-specific insertion of T2A-eGFP gene was checked on 18 isolates by PCR using primers outside the 
region of insertion into the BAC genome. Two isolates, A6 and C9, showed the expected 1.7-Kb PCR amplification 
band. (C): Diagnostic FIGE. A6 and A9 were compared to the original KBBJ and the KBBJ-CS-A and KBBJ-CS-C 
backbones by FIGE. A6 showed a shift-down in the HindIII pattern of digestion of its 20.5-Kb band towards the 19.5-
Kb band, evidence of an unexpected secondary recombination event in the BAC (yellow arrows). C9 instead showed 
for both digestions only the desired 400-bp shift of the gC-containing DNA band, while the remaining digestion 
pattern remained intact. 
 
Figure 10: 2nd step: counter-selection (CS) replacement with T2A-eGFP in gC 3’UTR. 
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As shown by the yellow arrows in the Figure 10C, KBBJ-T2A-eGFP-A6 showed a shift-down 
in the HindIII pattern of digestion of its 20.5-Kb band towards the 19.5-Kb band, evidence of an 
unexpected incorrect secondary recombination event in the BAC. KBBJ-T2A-eGFP-C9 instead 
showed for both digestions only the correct 400-bp shift of the gC-containing DNA band, while 
the remaining digestion pattern remained intact. The KBBJ-T2A-eGFP-C9 isolate (renamed 
KBGillustrated in Table 5) was then selected and transfected into U2OS cells to ensure the 
ability of the BAC-DNA to produce virus as described in section 2.7.4. 
 
2.7.2 Insertion of 4xT124 responsive element in ICP4-3’UTR 
 
2.7.2.1 Generation of pEntr-ICP4-T124-Kan 
 
To insert the 4xT124 responsive element from the pLuc-T124 construct (section 2.5) into the 3’ 
UTR of the ICP4 gene, I had to generate an intermediate construct called pEntr-ICP4-T124-
Kan. The pEntr-ICP4-T124-Kan construct was generated in eight steps summarized in Figures 
11-13. 
In step one, two partially overlapping single-strand 5’-phosphorylated DNA oligos including 
the ICP4 stop codon, the 3’-end of the ICP4 gene and an SpeI restriction site were designed 
(see Table 4). The two lyophilized oligos were dissolved in water to a final concentration of 3 
ug/μl. To anneal the two oligos, 1 μl of each oligo was combined with 48μl of annealing buffer 
(10 mM Tris Ph 7.5-8.0, 50 mM NaCl, 1 mM TE) and incubated at 95°C for 4’, shifted to 70°C for 
a 10’ incubation, shifted to room temperature (RT) for a 30’ incubation, and then stored at 4°C. 
The annealed, partially overlapping oligos were then elongated using Accuprime Pfx DNA 
polymerase (Invitrogen) for 30’ at 68°C to close the gaps generating a perfectly annealed 93-bp 
long double-stranded ICP4 DNA fragment (Figure 11-Step 1).  
In step two, 1 μl of the annealed ICP4 DNA fragment was ligated into the pZero-blunt vector 
(Invitrogen), transformed into DH10β competent bacteria (NEB), plated on kanamycin (100 
μg/ml) agar plates and incubated overnight at 37°C. Following selection the DNA extracted from 
the kan-resistant ICP4-pZero colonies was screened for insertion of the annealed oligo between 
two EcoRI sites through diagnostic EcoRI (NEB) digest. Two ICP4-pZero clones were selected 
and sent for sequencing to verify the integrity of the amplified sequence (Figure 11-Step 2). In 
step three, one selected ICP4-pZero isolate and the pLuc-T124 construct (described in section 
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2.5.2) were digested with EcoRI + SpeI (NEB) for 1 h at 37°C. The ICP4-pZero 81-bp fragment 
(insert) and 5-Kb pLuc-T124 backbone were gel purified and ligated together. 
 
 
 
 
 
Figure 11: Schematic of pEntr-ICP4-T124-kan generation, Steps 1-3. 
Step 1. Two partially overlapping single-strand 5’-phosphorylated DNA oligos including the ICP4 stop codon, the 3’-
end of the ICP4 gene and an SpeI restriction site were designed, annealed and elongated, generating a perfectly 
annealed 93-bp long double-stranded ICP4 DNA fragment. Step2. The annealed ICP4 DNA fragment was ligated into 
the pZero-blunt vector. Following cloning in bacteria and diagnostic digest for correct insertion of the oligo, two ICP4-
pZero clones were selected and sent for sequencing to verify the integrity of the amplified sequence. Step 3. One 
selected ICP4-pZero isolate and the fLuc-4xT124 construct (described in Figure 4) were digested with EcoRI + SpeI 
and ligated together. Following cloning into bacteria, fLuc-4xT124-ICP4 colonies were screened for insertion of the 
ICP4 fragment into the fLuc-4xT124 vector through EcoRI + SacI diagnostic digest. 
 
 
The ligation product was then transformed into DH10β competent bacteria (NEB), plated on 
ampicillin (100 μg/ml) agar plates and incubated overnight at 37°C. Following selection, the 
DNA from pLuc-T124-ICP4 amp-resistant colonies was screened for insertion of the ICP4 
fragment into the pLuc-T124 vector through EcoRI + SacI diagnostic digest (Figure 11-Step 3). 
In step four, the 4xT124-ICP4 portion of the pLuc-T124-ICP4 plasmid generated in step 3 
was extended by PCR with an ICP4 upper primer (ICP4-F) that overlapped the ICP4-oligo-F 
used in step one, and a lower primer (ICP4-R) containing a SacI restriction site and the polyA 
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region of ICP4. The PCR reaction was performed using Thermo Scientific® Phusion High-
Fidelity DNA Polymerase (NEB) according to the manufacturer’s instructions supplemented with 
1 μl of the pLuc-T124-ICP4 plasmid as template (200 ng/μl) and 1 μl of each primer (ICP4-F, 
ICP4-R 10 pmol/μl). The cycling protocol used was the following: 98°C for 30’’, 25 cycles x 
(98°C  for 10’’, 58°C  for 10’’, 72°C  for 15’’), 72°C  for 10’, 4°C  forever (Figure 12- Step 4). 
In step five, the 237-bp 4xT124-ICP4polyA product was gel-purified and 1 μl of it was ligated 
into pZero-blunt vector (Invitrogen), transformed into DH10β competent bacteria (NEB), plated 
on kanamycin (100 μg/ml) agar plates and incubated overnight at 37°C. Following selection, 
DNA from kan-resistant 4xT124-ICP4polyA-pZero colonies were screened for insertion of 
4xT124-ICP4polyA between two EcoRI sites through diagnostic EcoRI (NEB) digest. Two 
pZero-4xT124T-ICP4polyA clones were selected and sent for sequencing to verify the integrity 
of the amplified sequence (Figure 12-Step 5). 
 
 
 
 
Figure 12: Schematic of pEntr-ICP4-T124-kan generation, Steps 4-6. 
Step 4. The 4xT124-ICP4 portion of the fLuc-4xT124-ICP4 plasmid generated in step 3 was extended by PCR with 
an ICP4 forward primer (ICP4-F) that overlapped the ICP4-oligo-F used in step one, and a reverse primer (ICP4-R) 
containing a SacI restriction site and the polyA region of ICP4. Step 5: The 237-bp 4xT124-ICP4polyA PCR product 
was ligated into pZero-blunt vector. Following cloning into bacteria and EcoRI diagnostic digest for correct insertion of 
4xT124-ICP4polyA fragment between two EcoRI sites, two pZero-4xT124-ICP4polyA clones were selected and sent 
for sequencing to verify the integrity of the amplified sequence. Step 6: One pZero-4xT124-ICP4polyA isolate and the 
pEntr1A plasmid were digested with EcoRI and ligated together. Following cloning into bacteria, pEntr-T124-
ICP4polyA kan-resistant colonies were screened for insertion of the 4xT124-ICP4polyA fragment into pEntr1A 
through EcoRI diagnostic digest. 
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In step six, one of the sequenced pZero-4xT124-ICP4polyA isolates and the pEntr1A 
plasmid (Invitrogen) were digested with EcoRI (NEB) for 1 h at 37°C. The 4xT124-ICP4polyA 
250-bp fragment (insert) and 3.4-Kb pEntr1A backbone were gel purified, ligated together and 
transformed into DH10β competent bacteria (NEB), plated on kanamycin (100 μg/ml) agar 
plates and incubated overnight at 37°C. Following selection, pEntr-T124-ICP4polyA kan-
resistant colonies were screened for insertion of the 4xT124-ICP4polyA fragment into pEntr1A 
through EcoRI diagnostic digest (Figure 12-Step 6).  
In step seven, a plasmid containing the I-SceI restriction site next to a kanamycin resistance 
gene (I-SceI-kan cassette), kindly donated by Dr N. Osterrieder (Cornell University, Ithaca, NY, 
USA), was PCR amplified with I-SceI-Kan-F and I-SceI-Kan-R primers to insert two direct 
repeats (dr) on both sides of the cassette.  
The direct repeats were designed to contain a combination of three restriction sites for pI-
SceI, NotI and SacI enzymes. The PCR reaction was performed using Thermo Scientific® 
Phusion High-Fidelity DNA Polymerase (NEB) according to the manufacturer’s instructions 
supplemented with 1 μl of the I-SceI-kan cassette containing plasmid as template (200 ng/μl) 
and 1 μl of each primer (I-SceI-Kan-F and I-SceI-Kan-R 10 pmol/μl). The cycling protocol used 
was the following: 98°C  for 30’’, 25  cycles x (98°C  for 10’’, 63°C  for 10’’, 72°C  for 15’’), 72°C  
for 10’, 4°C  forever (Figure 13-Step 7).  
In step eight, both the I-SceI-Kan-dr (insert) from step seven and the pEntr-T124-ICP4polyA 
(backbone) from step six were digested with SacI for 1 h at 37°C, gel purified and ligated 
together. The ligation product was then transformed into DH10β competent bacteria (NEB), 
plated on kanamycin (100 μg/ml) agar plates and incubated overnight at 37°C. Following 
selection the pEntr-ICP4-T124-kan kan-resistant colonies were screened for insertion of the I-
SceI-kan-dr fragment into pEntr-T124-ICP4polyA through XhoI diagnostic digest. The pEntr-
ICP4-T124-kan construct (illustrated in Table 5) was used for the pBad/I-SceI-Red/ET mediated 
insertion of 4xT124 in ICP4-3’UTR (Figure 13- Step 8).  
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Figure 13: Schematic of pEntr-ICP4-T124-kan generation Step 7-8. 
Step 7. A plasmid containing the I-SceI restriction site next to a kanamycin resistance gene (I-SceI-kan cassette), 
was PCR amplified with I-SceI-Kan-F and I-SceI-Kan-R primers to insert two direct repeats (dr) on both sides of the 
cassette designed to contain a combination of three restriction sites for pI-SceI, NotI and SacI enzymes. Illustrated is 
the sequence of the I-SceI/ Kan selection cassette with underlined the position of the amplification primers and the I-
SceI restriction site in bold. Step 8: Both the I-SceI-Kan-dr (insert) from step 7 and the pEntr-T124-ICP4polyA 
(backbone) from step six were digested with SacI and ligated together. Following cloning into competent bacteria, 
pEntr-ICP4-T124-kan kan-resistant colonies were screened for correct insertion of the I-SceI-kan-dr fragment through 
XhoI diagnostic digest. 
 
 
2.7.2.2 pBad/I-SceI modified Red/ET protocol to insert 4xT124 in 
ICP4-3’UTR 
 
The Red/ET recombination protocol works very poorly in HSV regions that are extremely 
repetitive and very GC rich like the ICP4 locus of HSV-1. To overcome this problem, our 
laboratory adapted a pBad/I-SceI modification to the original Red/ET protocol56. As illustrated in 
Figure 7, using this modified protocol I was able to insert a tandem array of four miR124 target 
sequences (4xT124), previously generated and tested by luciferase assay (see section 2.5), into 
the 3’ UTR of the ICP4 gene.  
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In the first step of the pBad/I-SceI modified Red/ET protocol KBG containing bacteria were 
electroporated with pRed/ET plasmid and selected on CM +Tet plates at 30°C  as previously 
described (see KBBJ bacteria pRed/ET electroporation in section 2.7.1). One pRed/ET positive 
colony was then randomly selected to host the recombination reaction in the ICP4 locus of KBG 
(KBG-R illustrated in Table 5). A 1.3-Kb DNA fragment containing the 4xT124 sequence in the 
3’UTR of ICP4, a kanamycin selection cassette flanked by direct repeats and an I-SceI 
restriction site was then amplified by PCR from the previously generated pEntr-ICP4-T124-Kan 
construct (see section 2.7.2) as illustrated in Figure 14. The PCR reaction was performed using 
High Fidelity Accuprime GC-rich DNA Polymerase (Invitrogen) according to the manufacturer’s 
instructions supplemented with 1 μl of the ICP4-4xT124-ISceI-Kan template (200 ng/μl) and 1 μl 
of each primer (ICP4-F and ICP4-R 10 pmol/μl). The cycling protocol used was the following: 
95°C for 5’, 25  cycles x (95°C  for 30’’, 60°C  for 30’’, 72°C  for 1’20’’), 72°C  for 10’, 4°C  
forever. The resulting 1.3-Kb 4xT124-ICP4-ISceI-Kan PCR product shown in Figure14 was gel-
isolated using the QIAEXII Gel extraction kit (QIAGEN) and resuspended in ddH2O.  
 
 
 
 
Figure 14:  PCR amplification of 4xT124-ICP4-ISceI-Kan selection-cassette to be inserted in ICP4 3’UTR. 
A 1.3-Kb DNA fragment containing the 4xT124 sequence in the 3’UTR of ICP4, a kanamycin selection cassette 
flanked by direct repeats and an I-SceI restriction site was amplified by PCR from the previously generated pEntr-
ICP4-T124-Kan construct illustrated in Figure 13, purified and sent for sequencing to verify the integrity of the 
amplified sequence.  
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The PCR purified fragment was then electroporated into KBG-R bacteria to recombine in the 
ICP4 locus as described in Figure 15A. 
For the electroporation, one KBG-R bacteria colony was inoculated in CM (15 μg/ml) + tet (3 
μg/ml) LB medium and grown overnight at 30°C with 220 rpm shaking. 30 μl of KBG-R overnight 
culture was inoculated into 1.4 mL of LB medium and incubated at 30°C for 2 h with 1100rpm 
shaking. KBG-R bacteria were induced to express the recombination proteins from pRed/ET 
through incubation of the 1.4 mL culture at 37°C with 0.35% of L-arabinose for 45’ while shaking 
at 220 rpm.  Bacteria were then collected and prepared for electroporation by washing them 3 
times with ddH2O and by resuspending in 20 μl of ddH2O. Bacteria were electroporated with 5 
μl of the 4xT124-ICP4-ISceI-Kan fragment using a Biorad GenePulserXcell electroporator 
(Voltage 1650 V, Capacitance 25 uF, Resistance 150 Ω, Cuvette 1 mm). Following 
electroporation, bacteria were incubated for 70’ at 37°C  with 220 rpm shaking to allow Red/ET 
mediated recombination between the homology arm-flanked selection cassette and the KBG 
genome in front of the 3’UTR of ICP4. Cells were finally plated on CM (15 μg/ml) + tet (3 μg/ml) 
+ kan (15 μg/ml) agarose plates and incubated at 30°C to avoid loss of Red/ET plasmid. 16 kan-
resistant recombinants were selected and BAC DNA was extracted. 
The site-specific insertion of the 4xT124-ICP4-ISceI-Kan cassette was checked by PCR on 
16 kan-resistant recombinants, using the same ICP4-F and ICP4-R previously employed to 
amplify the 4xT124-ICP4-ISceI-Kan cassette from the pEntr1A construct (see table 4). The ICP4 
region is very GC-rich and it is very hard to find primers able to amplify it, that why the ICP4-F 
and ICP4-R primers, which are internal to the inserted fragment, were used for the diagnostic 
PCR too. The PCR reaction was performed using High Fidelity Accuprime GC-rich DNA 
Polymerase (Invitrogen) according to the manufacturer’s instructions supplemented with 2 μl of 
BAC-DNA template (200 ng/μl) and 1 μl of each primer (ICP4-F and ICP4-R 10 pmol/μl). The 
cycling protocol used was the following: 95°C  for 5’, 25  cycles x (95°C  for 30’’, 60°C  for 30’’, 
72°C  for 1’20’’), 72°C  for 10’, 4°C  forever. As shown in Figure 15B, eight of the 16 isolates 
amplified 2 bands, the expected 1.3-Kb band plus one 130-bp band identical to the band 
amplified from the ICP4 3’UTR region of the KBG control without the 4xT124-ICP4-ISceI-Kan 
insertion. Of the 8 isolates that showed only the correct PCR band at 1.3-Kb, two (ICP4-
miR124t-kan-B and ICP4-miR124t-kan-C illustrated in Table 5) were selected and compared to 
the original KBG backbone by FIGE analysis after overnight digestion of 20 μl of each BAC-
DNA miniprep template with either MfeI, AflII or HindIII restriction enzymes. As shown in Figure 
15C both isolates showed a 1.3-Kb  shift up of the 20.7-Kb  band in the MfeI digest, a break of 
the 27.4-Kb  band in a 17.4-Kb + 11.3-Kb  bands in the AflII digest and a break of the 20.2-Kb 
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band in a 16.5-Kb + 6.5-Kb bands in the HindIII digest. No other non-specific changes in the 
pattern of digestion were found and both isolates were used for the following step.  
 
 
 
 
Figure 15: 1st step: I-SceI-kan selection cassette insertion in ICP4 3’UTR. 
(A): Schematic of the I-SceI-kan selection cassette insertion in ICP4 3’UTR. (B) Diagnostic PCR. The site-specific 
insertion of the 4xT124-ICP4-ISceI-Kan cassette was checked by PCR on 16 kan-resistant recombinants, using the 
same ICP4-F and ICP4-R used to generate the cassette in Figure 14. Eight of the 16 isolates amplified 2 bands and 
were discarded Of the 8 isolates that showed only the correct PCR band at 1.3-Kb, two (ICP4-miR124t-kan-B and 
ICP4-miR124t-kan-C) were selected and analyzed by FIGE. (C): Diagnostic FIGE. ICP4-miR124t-kan-B and ICP4-
miR124t-kan-C were compared to the original KBG backbone by FIGE analysis after overnight digestion with MfeI, 
AflII or HindIII restriction enzymes. Both isolates showed a 1.3-Kb shift up of the 20.7-Kb band in the MfeI digest, a 
break of the 27.4-Kb band in a 17.4-Kb + 11.3-Kb bands in the AflII digest and a break of the 20.2-Kb band in a 16.5-
Kb + 6.5-Kb bands in the HindIII digest. 
 
 
In the second step, both KBG-ICP4-miR124t-kan-B and KBG-ICP4-miR124t-kan-C bacterial 
colonies, still carrying the pRed/ET plasmid, were electroporated with the pBad/I-SceI 
expression plasmid (kindly provided by K. Osterrieder 53,56) coding for the I-SceI restriction 
enzyme driven by the pBad arabinose-inducible promoter and for ampicillin (Amp) resistance. 
The electroporation procedure was identical to the one used to electroporate the pRed/ET (see 
section 2.7.1). Transformed bacteria were plated on CM (15 μg/ml) + tet (3 μg/ml) + kan (15 
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μg/ml) + Amp (50 μg/ml) agarose plates and incubated at 30°C to avoid loss of Red/ET plasmid. 
One pBad positive colony for both KBG-ICP4-miR124t-kan-B and KBG-ICP4-miR124t-kan-C 
was then randomly selected to host the recombination reaction and kan-selection cassette 
removal in the ICP4 locus (Figure 16A).  
One day before electroporation ICP4-miR124t-kan-B and ICP4-miR124t-kan-C bacteria 
were inoculated and grown overnight in CM (15 μg/ml) + tet (3 μg/ml) + Amp (50 μg/ml) 
containing-medium without kan at 30°C with 220 rpm shaking. On the day of the electroporation 
100μl of ICP4-miR124t-kan-B and ICP4-miR124t-kan-C overnight cultures were inoculated into 
2.0 mL of LB medium and incubated at 30°C for 2 h with 220 rpm shaking. To induce KBG-
ICP4-miR124t-kan-B and KBG-ICP4-miR124t-kan-C to express the recombination proteins from 
pRed/ET and the I-SceI enzyme from pBad the 2.0 ml bacteria culture were mixed with 2 mL of 
LB media containing 2% of L-arabinose and incubated at 30°C  for 60’ with shaking. Bacteria 
cultures were then shifted to 37°C for 45’ and then incubated again for 60’ at 30°C to allow both 
the I-SceI-mediated cleavage at its unique site in the kan-resistant construct and the internal 
Red/ET-mediated recombination between the repeats flanking the kanamycin selection cassette 
to eliminate the cassette from the BAC DNA. Bacteria were then grown overnight on CM (15 
μg/ml) agar plates at 37°C  to allow loss of the pRed/ET plasmid, but not of the pBad plasmid 
that remains when bacteria are grown at 37°C . CM-resistant colonies were then picked and 
tested for kan-sensitivity by replica-plating on CM (15 μg/ml) + kan (15 μg/ml). Six CM-resistant, 
Kan-sensitive recombinants (KBG-ICP4-miR124t-B1-4 and KBG-ICP4-miR124t-C5-6) were 
selected and BAC–DNA extracted. The site-specific elimination of the I-SceI-kan selection 
cassette from the ICP4 locus was checked by PCR using the same ICP4-F and ICP4-R primers 
previously employed to detect the insertion of the 4xT124-ICP4-ISceI-Kan cassette inside the 
ICP4 region. The PCR reaction was performed using High Fidelity Accuprime GC-rich DNA 
Polymerase (Invitrogen) according to the manufacturer’s instructions supplemented with 2 μl of 
the BAC-DNA template (200 ng/μl) and 1 μl of each primer (ICP4-F and ICP4-R 10 pmol/μl). 
The cycling protocol used was the following: 95°C  for 5’, 25 cycles x (95°C  for 30’’, 60°C  for 
30’’, 72°C  for 1’20’’), 72°C  for 10’, 4°C  forever. As shown in Figure 16B, four isolates (KBG-
ICP4-miR124t-B2, B3, B4, and C1) out of six showed the expected 300-bp PCR amplification 
band indicative of the elimination of the I-SceI cassette when compared to the 1.3-Kb band 
amplified from the parental KBG-ICP4-miR124t-kan-B and KBG-ICP4-miR124t-kan-C BACs. 
The four positive isolates were then analyzed by FIGE and compared to both parental KBG 
and KBG-ICP4-miR124t-kan-C BACs backbones after overnight digestion of 20 μl of each BAC-
DNA miniprep template with MfeI, AflII or HindIII. 
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Figure 16: pBad-induced ISceI-kan selection cassette removal in ICP4 3’UTR. 
(A): Schematic of the I-SceI-kan selection cassette removal in ICP4 3’UTR. (B) Diagnostic PCR. The site-specific 
elimination of the I-SceI-kan selection cassette from the ICP4 locus was checked by PCR using the same ICP4-F and 
ICP4-R primers used in the previous step. Four isolates (KBG-ICP4-miR124t-B2, B3, B4, and C1) showed the 
expected 300-bp PCR amplification band indicative of the elimination of the I-SceI cassette when compared to the 
1.3-Kb band amplified from the parental BACs. (C): Diagnostic FIGE. The four positive isolates were compared to 
both parental KBG and KBG-ICP4-miR124t-kan-C BACs backbones after overnight digestion with MfeI, AflII or 
HindIII. Three isolates (KBG-ICP4-miR124t-B3, B4, C1) showed the right pattern of digestion: in the MfeI digest, the 
band that shifted from 20.7-Kb up to 22-Kb with the insertion of the I-SceI-kan, shifted down to 20.8-Kb ; in the AflII 
digest, the 17.4-Kb band formed by the breakage of the 27.4-Kb band, shifted down to 16.3-Kb ; and in the HindIII 
digest, the 15-Kb  band plus a 6.5-Kb  band fused to form a 20.4-Kb band, forming a doublet on the gel with a 
preexisting 20.2-Kb  band. (D): Schematic of the structure of the ICP4-miR124t after sequencing.  
 
 
As shown in Figure 16C, three isolates out of four (KBG-ICP4-miR124t-B3, B4, C1) showed 
the right pattern of digestion: in an MfeI digest, the band that shifted from 20.7-Kb up to 22-Kb  
with the insertion of the I-SceI-kan, shifted down to 20.8-Kb ; in an AflII digest, the 17.4-Kb band 
formed by the breakage of the 27.4-Kb band, shifted down to 16.3-Kb ; and in a HindIII digest, 
the 15-Kb  band plus a 6.5-Kb  band fused to form a 20.4-Kb band, forming a doublet on the gel 
with a preexisting 20.2-Kb  band. No other non-specific changes in the pattern of digestion were 
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found. BAC DNA from all three isolates was then sent for sequencing to verify the integrity of 
the ICP4-3’UTR region (Figure 16D). To clean the bacteria from the ampicillin-containing pBad 
plasmid, responsible for the presence of extra-bands on the FIGE restriction digest between 4-
Kb and 6-Kb, the DNAs from the three positive recombinants KBG-ICP4-miR124t-B3, B4, C1 
were re-electroporated into fresh DH10β electrocompetent cells (NEB) that were than plated on 
CM (15 μg/ml) agar plates in the absence of amp to select for BAC-containing isolates without 
pBad plasmid. Briefly, frozen DH10β electrocompetent cells (NEB) were quickly thawed in ice 
and electroporated with 5 μl of KBG-ICP4-miR124t-B3, B4, C1 DNA using a Biorad 
GenePulserXcell electroporator (Voltage 1650 V, Capacitance 25 uF, Resistance 150 Ω, 
Cuvette 1 mm).  
 
 
Figure 17: pBad plasmid removal. 
10 isolates were analyzed by overnight digestion with HindIII and FIGE analysis for loss of the pBad plasmid. 9 out of 
10 isolates lost pBad while maintaining the BAC-DNA integrity.  
 
 
Following electroporation bacteria were incubated for 45’ at 37°C  with shaking then plated 
on CM (15 μg/ml) agarose plates and grown at 37°C  overnight. Ten CM-resistant isolates were 
picked and BAC–DNA extracted. The 10 isolates were then re-analyzed by FIGE for loss of the 
pBad plasmid after overnight digestion of 20 μl of each BAC-DNA miniprep template with 
HindIII. As shown in Figure 17, 9 out of 10 isolates lost pBad while maintaining the BAC-DNA 
integrity. The DNA from isolate KBG-ICP4-miR124t-C1-10 (renamed ICP4-miR124t-BAC 
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illustrated in Table 5) was randomly selected to be transfected in U2OS cells to ensure the 
ability of the BAC-DNA to produce eGFP expressing virus 
 
2.7.3 BAC minipreps 
 
Following electroporation and selection on agar plates BAC-transformed bacteria cells were 
picked and BAC–DNA extracted following the “Miniprep-Alkaline Lysis for BACs” protocol from 
Untergasser’s 
Lab (http://untergasser.de/lab/protocols/miniprep_alkaline_lysis_for_bacs_v1_0.htm). The BAC-
DNA was then checked for correct manipulation using both diagnostic PCR and FIGE analysis.  
 
2.7.4 Transfection of BAC-DNA into U2OS to produce KBG and ICP4-
miR124t-BAC oHSV-1 viruses 
 
KBG and ICP4-miR124t-BAC were transfected into U2OS cells to ensure the ability of the BAC-
DNA to produce virus. On the day before transfection cells were plated at a density of 1.2x106 
cells /well. 24 h later 80% confluent cells were transfected with 40 μl of either KBG or ICP4-
miR124t-BAC DNA using Lipofectamine LTX (Invitrogen) following the manufacturer’s 
instructions. Cells were incubated at 37°C in 5% CO2 and observed by fluorescence microscopy 
for eGFP expression every 24 h up to 72 h post transfection. Fluorescent pictures of either KBG 
or ICP4-miR124t-BAC infected cells were taken using a Nikon Diaphot fluorescent microscope. 
 
2.7.5 Transfection of BAC-DNA into U2OS-Cre cells to produce BAC-free 
KG and ICP4-miR124t oHSV-1 viruses 
 
To eliminate the loxP-flanked BAC, which has been shown to negatively affect viral growth 53 
both KBG and ICP4-miR124t BAC DNAs were converted into virus by transfection into U2OS-
Cre cells already available in the laboratory 55,56. Loss of the BAC region, which also contained 
the LacZ reporter gene, was determined by staining the infected cells for X-gal. On the day 
before transfection cells were plated as a 50% confluent monolayer on 2 wells of a 6 well dish at 
a density of 1.2x106 cells/well. 24hrs later, 80% confluent cells were transfected with 40 uL of 
either KBG or ICP4-miR124t-BAC DNA using Lipofectamine LTX (Invitrogen) following the 
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manufacturer’s instructions and then incubated at 37°C in 5% CO2. 72 h post transfection viral 
supernatant was collected, titered and used to perform a viral limiting dilution on regular U2OS 
cells as follows: 1x106 cells were infected with 30 plaque forming units (p.f.u ) of virus, plated in 
a 96 well dish, and incubated at 37oC for 5-7 days to allow plaque formation. Virus from wells 
with single plaques was collected, expanded, and used to infect U2OS cells. 48 h after infection 
cells were fixed with 1% glutaraldeyde solution for 1’, then washed twice with PBS and 
incubated for 30’-1 h at 37 oC with X-gal solution (X-gal 1 mg/ml, 0.25% deoxycholate, 0.8% 
NP40, 200 mM MgCl2, 5 mM potassium-ferricyanide, 5 mM potassium-ferrocyanide). After X-
gal staining, cells were washed twice with PBS and checked for presence or absence of blue 
color in the infected cells; viral clones in which no color change could be observed indicated 
Cre-recombinase mediated removal of the DNA region between the loxP sites. One lacZ-
negative viral clone was then selected for both KG (BAC removed illustrated in Table 5) and 
ICP4-miR124t (BAC removed illustrated in Table 5) and checked by PCR with primers outside 
the BAC region for clean removal of the region between the loxP sites. The PCR reaction was 
performed using High Fidelity Accuprime GC-rich DNA Polymerase (Invitrogen) according to the 
manufacturer’s instructions supplemented with 2 μl of the viral DNA template (200 ng/μl) 
extracted using the DNAeasy Blood and Tissue Kit (QIAGEN) according to the manufacturer’s 
instructions and 1 μl of each primer (UL-37-F and UL38-R 10 pmol/μl).  
The cycling protocol used was the following: 95°C  for 5’, 25 cycles x (95°C  for 30’’, 60°C  
for 30’’, 72°C  for 1’20’’), 72°C  for 10’, 4°C  forever. The PCR in Figure 18 shows a 600-bp 
band expected after correct removal of the BAC in both KG and ICP4-miR124t. The two primers 
couldn’t amplify the expected 10-kb band in the control sample KGB because the extension time 
of the PCR cycle was not long enough 
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Figure 18: PCR to verify correct removal of the BAC after infection of U2OS-Cre cells. 
After X-gal staining one lacZ-negative viral clone was selected for both KG and ICP4-miR124t and checked by PCR 
with primers outside the BAC region for clean removal of the region between the loxP sites. Both KG and ICP4-
miR124t isolates showed a 600-bp band expected after correct removal of the BAC. The two primers couldn’t amplify 
the expected 10-kb band in the control sample KGB. 
. 
 
2.8  Creation of Tet-on-miR124 stable cell line 
 
2.8.1 Extraction of total DNA from U87 cells 
 
Both human pri-miR124 and pri-miR137 sequences were PCR amplified using the genomic 
DNA extracted from U87 (human grade IV glioblastoma cell line) as a template. To extract DNA 
from U87 cells, 9x106 cells were first incubated in a Proteinase K (Sigma) digestion cocktail (10 
mM Tris pH=7.5, 100 mM NaCl, 10 mM EDTA, 0.5% SDS, 0.2 mg/ml Proteinase K) at 50°C  for 
4 h with light vortexing every 45’. The digestion mixture was then combined with one volume of 
(25:24:1 v/v) Phenol/Chloroform/Isoamil Alchool solution (solution) and centrifuged at maximum 
speed for 15’. The top layer was then combined with one volume of Chloroform and centrifuged 
at maximum speed for 10’. The top layer was then combined with 2.5 volumes of 100% EtOH 
(ethyl alcohol) and left at -20°C overnight to allow precipitation of DNA. The DNA then was 
centrifuged 10’ at maximum speed, the pellet washed twice with 70% EtOH and finally 
resuspended in ddH2O. 
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2.8.2 Engineering of a Tet-On-miR124 construct 
 
To generate an inducible cell line expressing miR124, I generated a Tet-On-miR124 construct in 
two steps. In the first step, illustrated in Figure 19, the rtTA gene was PCR amplified from a pgk-
rtTA-Sv40polyA plasmid (kindly donated By Dr. Richard Chaillet, University of Pittsburgh) with 
BrtTA-F and NrtTA-R primers, designed to carry a BglII and a NotI restriction sites. The rtTA 
PCR reaction was performed using High Fidelity KOD DNA Polymerase (Millipore) according to 
manufacture instructions supplemented with 0.5 ul of pgk-rtTA-Sv40polyA template (200 ng/ul) 
and 1 ul of each primer (BrtTA-F and NrtTA-R 10 pmol/ul). The cycling protocol used was the 
following: 95°C for 1’, 25 cycles x (95°C for 30’’, 60°C for 30’, 72°C for 40’’), 72°C for 10’, 4°C 
forever. The 750-bp rtTA PCR product was ligated into pZero-blunt vector (Invitrogen). One 
rtTA-pZero positive clone was selected and sent for sequencing to verify the integrity of the 
amplified sequence. The rtTA gene was then inserted between BamHI and NotI sites in a 
pCDNA3.1 expression plasmid (Invitrogen) between the CMV promoter (pCMV) and the bovine 
growth hormone polyadenylation (bGH-polyA) signal. The BamHI and NheI sites from the 
pCDNA-rtTA construct were eliminated to facilitate the future cloning steps by digesting with 
BamHI and NheI and blunting with Klenow DNA polymerase (NEB). The expected 6.7-Kb band 
was gel purified, re-ligated, and screened through BamHI and NheI diagnostic digest to ensure 
that both restriction sites had been eliminated (Figure 19A) The TetO promoter was isolated 
from TetO-pks construct (kindly donated By Dr. R. Chaillet, University of Pittsburgh) and 
inserted into pDsRed2.1 expression plasmid (Clonetech) between XhoI and EcoRI restriction 
sites (Figure 19B). The resulting construct, called DsRed-TetO, was used as backbone to create 
DsRed-TetO-rtTA by digestion with XmaI and AflII and blunting by Klenow DNA polymerase 
(NEB). pCMV-rtTA-bGH-polyA was excised from the previously generated pCDNA-rtTA with 
Bpu10I and PvuII, blunted by Klenow DNA polymerase and insterted into the DsRed-TetO 
backbone (Figure 19C).  
In the second step, illustrated in Figure 20, using as template the genomic DNA extracted 
from U87 as described in section 2.8.1, the human pri-miR124 sequence was PCR amplified 
from the hsa-mir124-3 gene (located on chromosome 20q13.33) with primers Bmir124-F and 
NmiR124-R designed to carry a BamHI and a NheI restriction sites to simplify the cloning 
procedure. The pri-miR124 PCR reaction was performed using High Fidelity Accuprime GC-rich 
DNA Polymerase (Invitrogen) according to manufacture instructions supplemented with 2.5 ul of 
U87 total DNA template (100 ng/ul) and 1ul of each primer (miR124-F and miR124-R 10 
pmol/ul). 
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Figure 19: Generation of the TetO-inducible miR124-expressing construct: Step 1. 
(A): cloning of the rtTA gene. The rtTA gene was PCR amplified from a pgk-rtTA-Sv40polyA plasmid with BrtTA-F 
and NrtTA-R primers. The 750-bp rtTA PCR product was ligated into pZero-blunt vector. The rtTA gene from one 
selected and sequenced rtTA-pZero clone was then inserted between BamHI and NotI sites in a pcDNA3.1 
expression plasmid between the CMV promoter (CMVp) and the bovine growth hormone polyadenylation (bGH-
polyA) signal. The BamHI and NheI sites from this pcDNA-rtTA construct were then eliminated. (B): Cloning of the 
TetO promoter. The TetO promoter was isolated from TetO-pks and inserted into pDsRed2.1 expression plasmid 
between XhoI and EcoRI restriction sites. The construct was called DsRed-TetO. (C): Cloning of TetO promoter and 
rtTA gene together in the same plasmid. pCMV-rtTA-bGH-polyA was excised from the pCDNA-rtTA with Bpu10I and 
PvuII, blunted and inserted in DsRed-TetO used as backbone after digestion with XmaI and AflII and blunting. The 
construct was called DsRed-TetO-rtTA.  
 
 
The cycling protocol used was the following: 95°C for 5’, 32 cycles x (95°C for 1’, 55°C for 
1’, 72°C for 30’’), 72°C for 10’, 4°C forever. The 320-bp pri-miR124 PCR product was inserted 
into pZero-blunt vector and a pZero-miR124 positive clone was selected and sent for 
sequencing to verify the integrity of the amplified sequence (Figure 20A). The pri-miR124 
fragment was then inserted in the miRNASelect pEP-miR Cloning and Expression Vector (Cell 
Biolabs Inc.) between BamHI and NheI cloning sites, designed to insert pri-miR sequences 
within an intron in the 5’ UTR of the rPuro (Puromycin-resistance) gene. The resulting construct 
was called pEP-miR124 (Figure 20B and Table 5). The intron-miR124-rPuro cassette was 
removed from pEP-miR124 by Acc65I and AclI digest and was placed behind the TetO-
inducible promoter in the DsRed-TetO-rtTA by blunt end cloning into a SacII site. 
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Figure 20: Generation of the TetO-inducible miR124-expressing construct Step 2. 
(A): The human pri-miR124 sequence was PCR amplified from the hsa-mir124-3 gene (located on chromosome 
20q13.33) of the U87 cells total DNA with primers Bmir124-F and NmiR124-R. The 320-bp pri-miR124 PCR product 
was inserted into pZero-blunt vector. One positive pZero-miR124 clone was selected and sent for 
sequencing. (B): The pri-miR124 fragment was then cloned from pZero-miR124 to a miRNASelect pEP-miR Cloning 
and Expression Vector between BamHI and NheI cloning sites, within an intron in the 5’ UTR of the rPuro 
(Puromycin-resistance) gene. (C): The intron-miR124-rPuro cassette was removed from pEP-miR124 by Acc65I and 
AclI digest and was placed behind the TetO-inducible promoter in the DsRed-TetO-rtTA by blunt end cloning into a 
SacII site. The resulting construct was called TetO-miR124. 
 
 
The resulting construct was called TetO-miR124 (Figure 20Cand Table 5). To be used as 
control for TetO-miR124, a TetO-intron (Table 5) inducible construct without miRNA was 
created by digesting TetO-miR124 with BamHI and NheI (NEB) to remove the miR, then 
blunting through Klenow DNA polymerase (NEB) and religating.  
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2.8.3 U2OS transfection and selection of stable clones 
 
The TetO-miR124 and TetO-intron constructs, which express the neomycin (neo) resistance 
gene, were transfected in U2OS cells to make a TetO inducible stable cell lines. On the day 
before transfection cells were plated as monolayer at 50% confluency on 2 wells of a 6 well 
plate at a density of 0.5x106 cells /dish. 24 h later 80% confluent cells were transfected with 
either TetO-miR124 or TetO-intron using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s instructions. Cells were than incubated at 37°C in 5% CO2. 24 h after 
transfection cells were treated with 0.75 mg/ml G-418 (50 mg/mL, Gemini), obtaining a mixed 
population of U2OS cells expressing Tet-inducible miR124 (U2OS-Tet-miR124 cells) or Tet-
inducible control cells (U2OS-Tet-control). Single clones of stably transfected U2OS-Tet-
miR124 and U2OS-Tet-control cells were then isolated through limiting diluition in G418 
selection. 60 U2OS-Tet-miR124 and 10 U2OS-Tet-control cell clones were then tested for 
miR124 expression after doxycycline (Dox, Sigma) induction. One day before treatment each 
clone was plated on 2 wells of a 48 well plate at a density of 0.5x105 cells/dish. 24 h later cells 
were treated with (1 µg/ml) of Dox and incubated at 37°C in 5% CO2 for 48 h. Total RNA was 
collected from each clone using Trizol (Invitrogen) according to the manufacturer’s instructions. 
RT-qPCR on the total RNA extracted was then performed as described in section 2.8.4. The 
miR124 expression was calculated relative to the expression of RNU-43 a small RNA used as 
internal control.  
 
2.8.4 RT-qPCR for miR124 quantification  
 
RT-qPCR was performed on total RNA reverse transcribed from cell sample using the TaqMan 
Small RNA Assay kit (Applied Biosystems), that included both the RT primers and the qPCR 
primers for both hsa-miR-124a and hsa-RNU-43, a small RNA used as internal control, following 
the manufacturer’s instructions. The RT primers were used together with the TaqMan MicroRNA 
Reverse Transcription kit (Applied Biosystems) to reverse-transcribe 10 ng of Trizol-extracted 
total RNA, while the qPCR primers were used to measure the amount of miR124 and RNU-43 
present using StepOne Plus Real Time PCR System (Applied Biosystem). The thermal cycling 
conditions used were the following: 50ºC for 2’, 95ºC for 10’, 40 cycles x (95ºC for 15’’, 60ºC for 
1’). Mir124 expression relative to RNU-43 expression was then calculated using the 
comparative CT method according to the manufacturer’s instructions (Applied Biosystems). 
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2.8.5 oHSV-1 infection of U2OS TetO stable lines, SHSY5Y, 50B11, PC12 
following miR-124 inducing drug treatment with either doxycycline (Dox), 
Forskolin or Nerve Growth Factor (NGF) 
 
To examine potential effects of induced miR124 expression on oHSV-1 activity, both KG and 
ICP4-miR124t viruses were tested in Tet-miR124-10, Tet-miR124-84 and Tet-negative-7 in 
presence or absence of a 48 h long doxycycline (Dox) treatment, 50B11 in presence or absence 
of a 48 h long Forskolin treatment, PC12 after a 7-14 days long NGF treatment and naïve 
SHSY5Y. One day before drug treatment, cells were plated at a 50% confluent monolayer. 24 h 
later cells were treated with either 10 µg/ml  Dox (Sigma), 75 µM Forskolin (Sigma), 50 ng/ml 
NGF(Sigma) or left untreated and incubated at 37ºC in 5% CO2 for as long as required by the 
specific treatment. Following treatments, cells were divided in two groups. On the first group 
total RNA was collected using Trizol (Invitrogen) according to the manufacturer’s instructions 
and RT-qPCR for miR124 expression was performed as described in section 2.8.4. The second 
group of cells was instead infected with either KG or ICP4-miR124t at the appropriate MOI 
(MOI= 0.01 and 0.001 for TetO stable clones; MOI= 0.1 for 50B11; MOI= 0.3 and 3 for PC12; 
MOI= 0.1, 0.01 and 0.001 for SHSY5Y cells). At different timepoint after infection (24, 48, and 
72 h PI for TetO clones; 24, 48, 72, 120, 196 h PI for 50B11; 48 and 120 h PI for PC12; 24, 48, 
96 h PI for SHSY5Y), cells and supernatants were collected and sonicated using the Ultrasonic 
Processor XL sonicator (Misonix Inc.) to free the virus still trapped inside cells. Viral 
supernatants were then cleaned from cellular debris through centrifugation at 3000 rpm for 10’ 
and titered on U2OS cells in p.f.u /ml to measure HSV replication (see Section 2.2.3).  
 
2.9 Creation of a transiently expressing Lenti-miR124 and Lenti-miR137A 
Primary Glioma Cells 
 
2.9.1 Engineering of pCDH-miR124 expression construct  
 
The pCDH-miR124 construct used to generate the Lenti-miR124 virus was engineered from the 
original lentiviral expression vector pCDH-CMV-EF1 (System Biosciences), as illustrated in 
Figure 21A.  
 
 50 
 
 
 
Figure 21: Generation of pCDH expression constructs. 
(A): Engineering of pCDH-miR124. the Puromycin (Puro) gene was PCR amplified using an upper primer (X-Puro-F) 
carrying a XbaI restriction site and a lower primer (XS-Puro-R) carrying a SalI and a XbaI restriction sites and 
inserted into pEP-124 construct (Figure 19) between two XbaI sites. The resulting construct was called pEP-miR124-
Puro. The EF1-intron-miR124-Puro expression cassette was excised from the Pep-miR124-Puro plasmid and 
inserted into the pCDH-CMV-EF1 lentiviral expression vector between ClaI and SalI sites. The resulting lentiviral 
construct was called pCDH-miR124. (B): Engineering of pCDH-miR137A. The human pri-miR137 sequence was PCR 
amplified with two primers, Nmir137-F carrying a NheI site and BmiR137-R carrying a BamHI restriction site, from the 
hsa-mir137 gene of U87 cells total DNA, located on chromosome 1p22. The pCDH-miR124 construct and the pri-
miR137 PCR product were digested with BamHI + NheI, gel purified and ligated together to create pCDH-miR137A 
with the miR137 sequence positioned in the reverse (anti-sense) orientation. 
 
 
First, the Puromycin (Puro) gene was PCR amplified using an upper primer (X-Puro-F) carrying 
a XbaI restriction site and a lower primer (XS-Puro-R) carrying a SalI and a XbaI restriction 
sites, to be inserted into pEP-124 construct (see section 2.8.2 step 2) between two XbaI sites. 
The PCR reaction was performed using High Fidelity Accuprime GC-Rich DNA Polymerase 
(Invitrogen) according to manufacture instructions supplemented with 1uL of the pCDH-CMV-
EF1 (200 ng/ul) and 1ul of each primer (X-Puro-F, XS-Puro-R 10 pmol/ul). The cycling protocol 
used was the following: 95°C for 5’, 30 cycles x (95°C for 30’’, 57°C for 30’’, 72°C for 1’), 72°C 
for 10’, 4°C forever. The resulting construct was called pEP-miR124-Puro. The EF1-intron-
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miR124-Puro expression cassette was excised from the Pep-miR124-Puro plasmid to be 
inserted into the pCDH-CMV-EF1 lentiviral expression vector between ClaI and SalI sites. The 
resulting lentiviral construct was called pCDH-miR124 (Table 5). 
 
2.9.2 Engineering of pCDH-miR137A control expression construct  
 
To have a control lentivirus to use during Lenti-miR124 infection, the pCDH-137A construct was 
created from the pCDH-miR124 construct by substituting the miR124 sequence with a miR137 
sequence cloned in opposite orientation as illustrated in Figure 21B.  
First, the human pri-miR137 sequence was PCR amplified with two primers, Nmir137-F 
carrying a NheI site and BmiR137-R carrying a BamHI restriction site, from the hsa-mir137 
gene, located on chromosome 1p22, using as template the genomic DNA extracted from from 
U87 cells as described in section 2.8.1. The pri-miR137 PCR reaction was performed using 
High Fidelity Accuprime GC-rich DNA Polymerase (Invitrogen) according to manufacture 
instructions supplemented with 2.5 uL of hES total DNA template (100 ng/ul) and 1ul of each 
primer (NmiR137-F and BmiR137-R 10 pmol/ul). The cycling protocol used was the following: 
95°C for 5’, 32 cycles x (95°C for 1’, 55°C for 1’, 72°C for 30’’), 72°C for 10’, 4°C forever. The 
297-bp pri-miR137 PCR product was then gel purified and resuspended in ddH2O. The pCDH-
miR124 construct created in section 2.9.1 and the pri-miR137 PCR product were digested with 
BamHI + NheI, gel purified and ligated together to create pCDH-miR137A (Table 5). 
 
2.9.3 Production of Lenti-miR124 and Lenti-miR137 viruses  
 
To produce all lentiviruses, the pCDH expression constructs were cotransfected with three 
pLenti packaging plasmids (PLP1, PLP2, PLP-VSVG) into 293T cells, the cell line of choice to 
produce high lentiviral titer. The day of transfection 10x106 cells were plated on two 10 cm 
dishes coated with poly-lysine (Sigma). 6 h later attached cells were co-transfected with 3 µg of 
either pCDH-miR124 or pCDH-miR137A plus a mixture of three pLenti packaging plasmids (1.5 
µg of pLP1, 1.0 µg of pLP2 and 1.5 µg of pLP-VSVG from Invitrogen) using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s instructions and incubated overnight at 
37ºC in 5%CO2. 24 h after infection cell medium was changed and cells were incubated at 33ºC 
in 5% CO2 for additional 48 h, a condition that blocks cells from overgrowing without interfering 
with viral replication. 72 h after transfection the cell supernatants containing the viruses were 
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collected, filtered through a 0.45 μm filter (Millipore) to clean it from impurities and centrifuged at 
7500 rpm for 16 h. Each viral pellet was then resuspended in DMEM and titered on 293T cells 
to assess lentivirus concentration for the subsequent transient expression assays. 
 
2.9.4 Lentivirus titration calculated in colony forming units (c.f.u. /ml) 
 
The day before lentivirus titration 80% confluent 293T cells were plated on a 6 well dish and 
incubated overnight at 37ºC in 5% CO2. 24 h later cells were infected with serial 10-fold dilutions 
of viral supernatant plus 8 µg/ml polybrene (Sigma), an enhancer of lentivirus infection, and 
incubated overnight at 37ºC in 5% CO2. 24h after infection cell medium was changed and cells 
were incubated with 8 µg/ml of puromycin (puro, Sigma), whose resistance gene was expressed 
from the pCDH backbone. Colonies of puromycin resistant pCDH expressing cells were counted 
10-15 days after initial infection and viral titer calculated in colony forming units (c.f.u. /ml). 
 
2.9.5 Lenti-miR124 infection of primary glioma cells 
 
To examine potential effects of lentiviral miR124 expression on primary glioma cells, such as 
neuronal differentiation or reduced cell viability, Gli68 and GBM30 primary glioma cells were 
infected with either Lenti-miR124 or Lenti-miR137A viruses.  On the day of the infection both 
cells, which were grown as spheroid aggregates, were broken up into single cells to allow viral 
infection. 2 x 105 cells/ virus were then counted and infected with either Lenti-miR124 or Lenti-
miR137A viruses at MOI of 5.0 based on 293T cells titration calculated in c.f.u /ml (see section 
2.9.4) in 1.5 ml of regular growth media plus 8 µg/ml polybrene. Cells were incubated with 
gentle rotation in 2.0 ml eppendorf tubes at 37ºC for 90’ and then plated on 2 wells of a 6 well 
plate. 24 h after infection cell medium was replaced with fresh medium and cells were selected 
with 30 µg/ml of puromycin whose resistance gene was jointly expressed with miR124 from the 
pCDH plasmid.  At 72 h after puromycin selection (96 hours after initial lentivirus infection), part 
of the cells was collected and total RNA was extracted using Trizol (Invitrogen) according to the 
manufacturer’s instructions to measure miR124 expression by RT-qPCR (see Section 2.8.4). 
Another part of the cells instead was super-infected with either ICP4-miR124t or KG virus at an 
MOI of 0.01 to test oHSVs response to miR124 expression (see Section 2.9.6) 
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2.9.6 KG and ICP4-miR124t oHSV infection of primary glioma cells 
 
On the day of the infection both GBM30 and Gli68 primary glioma cells, which were grown as 
spheroid aggregates, were broken up into single cells to allow viral infection. 2x105 cells were 
then counted and infected with either ICP4-miR124t or KG virus at MOI of 0.01 in 1.5 ml of 
regular growth media. Cells were then incubated with gentle rotation in eppendorf tubes at 37ºC 
for 90’ and then plated on a 48 well plate (2 wells per timepoint per virus). At 72 and 96 h post 
infection, cells and supernatants were collected and sonicated using the Ultrasonic Processor 
XL sonicator (Misonix Inc.) to free the virus still trapped inside cells. Viral supernatants were 
then cleaned from cellular debris through centrifugation at 3000 rpm for 10’ and titered on U2OS 
cells in p.f.u /ml to measure HSV replication (see section 2.2.3).  
 
2.10  In Vivo Toxicity Testing 
 
The ICP4-miR124t viral response to endogenous levels of miR124 was assessed in vivo by 
toxicity studies performed to evaluate potential immunologic and pathogenic effects on normal 
brain in tumor-free, immunodeficient NUDE BALB/c mice and in tumor free  immunocompetent  
BALB/c mice.  
 
2.10.1 Viral injections in immunocompetent mice 
 
Either KG or ICP4-miR124t virus was administered by intracranial stereotactic injection into the 
right temporal lobe (cortex) of 3 weeks old female regular BALB/c mice for a total of 3 mice per 
virus. A single dose of 4.8x109 genome-copies (gc) of each virus was tested by injecting each 
mouse with 4 µl of viral prep. Two animals, one for each virus, were sacrificed 3 hours after 
injection (hpi), while the remaining animals were left alive and monitored for general health 
(weight, activity, clinical signs) every other day after injection. At 5 days post injection (dpi) the 
first KG animal started giving signs of vector related pathology, specifically more than 30% 
weight loss, loss of activity, arched back, no grooming, and it was sacrificed together with one 
mouse injected with the ICP4-miR124t virus. The second KG animal was instead sacrificed at 
7dpi because, after being sick for the first 5 dpi, it started to show signs of recovery, possibly 
indicating of a change in viral yield in its brain. On the contrary, the second ICP4-miR124t 
injected virus was not sacrificed at that time, but was left alive to these days where it continues 
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to be monitored for general health. All animals were first sacrificed by saturating a sealed 
chamber with CO2 for 2 minutes, and then their entire brain was collected and stored in PBS.  
At this point, total DNA was extracted from each brain using the DNAeasy Blood and Tissue Kit 
(QIAGEN) according to manufacturer’s instructions. To determine the amount of viral genomes 
present in each brain compared to the amount of virus injected on day 0, qPCR for the HSV 
glycoprotein D (gD) gene was performed as described in section 2.2.4. 
 
2.10.2 Viral injections in immunocompromised mice 
 
Either KG or ICP4-miR124t virus was administered by intracranial stereotactic injection into the 
right temporal lobe (cortex) of 3 weeks old female nu/nu nude BALB/c mice for a total of four 
mice per virus. A single dose of 1.5x109 gc of each virus was tested by injecting each mouse 
with 4 µl of viral prep. The animals that survived from viral injection were sacrificed at 5, 14, 21 
and 33 dpi by saturating a sealed chamber with CO2 for 2 minutes and their entire brain 
collected and stored in PBS.  At this point, total DNA was extracted from each brain using the 
DNAeasy Blood and Tissue Kit (QIAGEN) according to manufacturer’s instructions. To 
determine the amount of viral genomes present in each brain compared to the amount of virus 
injected on day 0, qPCR for the HSV glycoprotein D (gD) gene was performed as described in 
section 2.2.4. 
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3 RESULTS  
 
 
 
3.1  Validation of the use of a joint deleted HSV-1 as backbone to create a GBM 
oncolytic vector 
 
The 152-kb HSV-1 genome is organized into a Unique Long (UL) and a Unique Short (US) 
region, each flanked by inverted repeats as shown in Figure 1. The junction between the 
internal repeats is called Joint and contains one copy of ICP0, ICP4 and γ34.5 genes; the 
unique regions can flip back and forth, creating four possible HSV isomers and making the HSV 
genome unstable and prone to internal recombination 15,16. The deletion of the joint freezes the 
HSV genome as one of its isomers, maintaining one copy of each of its diploid genes, ICP0, 
ICP4 and γ34.5, and stabilizing the vector against internal recombination events, facilitating 
accurate engineering without affecting virus ability to replicate and kill tumor cells in vitro. 
 Previous in vitro studies have demonstrated that deletion of the joint region of HSV-1 
produces a viable virus that can be grown in cell culture, meaning that this region is dispensable 
for viral replication in vitro 60. Vectors described in this study were derived from KOS-BAC (KB 
illustrated in Table 5), a complete HSV-1 strain KOS genome cloned on a bacterial artificial 
chromosome (BAC) and kindly donated by Dr. D.A. Leib 53. To facilitate vector engineering and 
stabilize the HSV genome, a joint deleted version of KB, KOS-BAC-∆J (KBJ illustrated in Table 
5), was previously created in our laboratory by deleting the KB internal repeat (Joint) region 
between UL56 and US12 including the portion corresponding to the ICP47 promoter. I 
examined the growth of KB and KBJ on two immortal cell lines routinely used in our laboratory 
for HSV propagation, Vero and U2OS, to confirm previous reports that the joint is dispensable 
for virus replication in vitro 60. 24 hours (h) and 48 h after initial infection at a multiplicity (MOI) of 
1, viral supernatants were collected and titered to quantify viral yields. As shown in Figure 22, 
both KB and KBJ exponentially replicated in both cell lines with a difference in titer between the 
two viruses of only about 4 times in U2OS and 10 times in Vero cells at 48 h post- infection 
(hpi), demonstrating that the deletion of the joint region of HSV-1 does not dramatically 
decrease the ability of the virus to replicate in tumor cells in vitro.  
These results show that a joint-deleted HSV-1 virus constitutes a good platform for the 
development of an oncolytic virus against GBM because it is comparable to its non-deleted 
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counterpart in terms of replication in immortalized cells in vitro, while more stable and easier to 
engineer than its deleted counterpart. 
 
 
 
 
Figure 22: Replication efficiency of Joint deleted KOS-BAC (KBJ) in vitro 
Both Vero and U2OS cells were infected with either KOS-BAC (KB) or KOS-BAC-∆J (KBJ) viruses. At 24hrs and 
48hrs after initial infection viral supernatants were collected and titered on Vero cells. Plates were then fixed and 
stained with crystal-violet. Viral plaques were counted and viral titer was calculated. The mean value ±standard 
deviations from three determinations are illustrated. The chart shows no difference in viral growth between the two 
viruses  
  
 
3.2 Testing of a firefly-Luciferase expression plasmid (pLuc) carrying the 
miR124 responsive element 4xT124 
 
To test the ability of a miR124 responsive element (T124) to efficiently block protein expression 
when inserted in the 3’UTR of a target gene, a tandem of four copies of the miR124 target 
sequence (4xT124) obtained from the miRBase online database (http://www.mirbase.org/cgi-
bin/mirna_entry.pl?acc=MI0000443) was inserted in the 3’UTR of the luciferase reporter gene in 
a firefly-Luciferase (fLuc) expression plasmid (pLuc-T124), as shown in Figure 4 (see Section 
2.5 for construct description). A similar construct called pLuc-Tcon was created using a tandem 
of 4 copies of a random sequence without complementarity to miR124 to be used as control. To 
verify that the presence of miR124 effectively blocked luciferase activity, both constructs were 
co-transfected with a renilla luciferase (rLuc) internal control plasmid into U2OS and HEK293AD 
cells transiently expressing either miR124 or an unrelated control miRNA (miR21) transfected 
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24h earlier as pre-miRNAs. Cells where collected 48h after the second transfection, lysed, and 
luciferase activity in cell lysates was measured using a luminometer.  
The results in Figure 23, normalized to rLuc activity, show a miR124-dependent 96% 
decrease in fLuc activity in HEK293AD expressing pLuc-T124 and an 89% decrease in U2OS 
cells. In contrast, no difference in fLuc activity was detected in either cell line expressing pLuc-
Tcon or in miR21-transfected cells. These results demonstrated that the 4xT124 element is 
specifically responsive to miR124 expression, suggesting it could be introduced in the 3’UTR of 
the ICP4 gene to impede HSV-1 replication in miR124-expressing cells such as normal 
neurons. 
 
 
 
 
Figure 23: MiR124-controlled Luciferase Activity. 
Both pLuc-T124 and pLuc-Tcon constructs were co-transfected with a renilla luciferase (rLuc) internal control plasmid 
into two different cell lines, HEK293AD and U2OS, transfected 24 h earlier with synthetic pre-miR124 or pre-miR21. 
48 h after the Luc transfections cells where collected, lysed and luciferase activity in cell lysates was measured using 
a luminometer. The results normalized to rLuc activity represent the mean value ±standard deviations from three 
determinations. Charts show strong inhibition of the luciferase activity only in cells expressing both pLuc-124 and pre-
miR124. 
 
3.3 Engineering and Production of a ICP4-miR124T oHSV-1 Oncolytic Vector 
 
3.3.1 Engineering of the HSV-1 genome. 
 
To generate the final ICP4-miR124t-BAC construct I added two modifications to the parental 
KOS-BAC-gBN/T-∆J (KBBJ), as described in section 2.7 (Figure 5). KBBJ was derived from the 
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joint-deleted KBJ backbone by introducing a double mutation in gB, D285N/A549T, named 
(gB:NT) 57. All the schematics of the described BAC constructs are illustrated in Table 5. 
The parental KBBJ was first modified by in-frame fusion of an eGFP gene preceded by a 2A 
translation-pause sequence with the last residue of the resident late viral gC gene (Figure 6). 
This first modification was generated to use eGFP green expression as a marker for viral 
replication and spread in infected cells both in vitro and in vivo. Using Red/ET recombination, a 
kan/strep counter-selection cassette was initially inserted in front of the gC stop codon. This 
cassette was then replaced with the T2A-eGFP sequence to create KOS-BAC-gBN/T-∆J-
gCeGFP (KBG). Both Red/ET mediated recombination steps were confirmed by PCR using 
primers flanking the insertion site and by FIGE to ensure that recombination had occurred 
correctly without major rearrangements elsewhere in the HSV genome. Compared to the parent 
KBBJ, PCR analysis of 5 isolates from the first recombination step showed the expected 1.3-Kb 
increase in the size of the amplified product caused by the counter-selection cassette insertion 
(Figure 9B), and FIGE analysis showed a 1.3-Kb upward shift of a HindIII fragment containing 
the intended insertion site (Figure  9C). After the second recombination step, only 2 isolates 
showed the 400-bp decrease in the size of the PCR product expected for correct replacement of 
the counter-selection cassette by the shorter T2A-eGFP sequence (isolates A6, C9, Figure 
10B).  
 
 
 
Figure 24: KBG BAC-DNA transfection into U2OS to verify BAC-DNA ability to generate virus. 
Following transfection, cells were incubated at 37°C in 5% CO2 and observed by fluorescence microscopy for eGFP 
expression every 24 h up to 72 h post transfection. Fluorescent pictures of actively replicating and spreading KBG 
into infected cells were taken using a Nikon Diaphot  fluorescent microscope.  
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Although FIGE analysis of BglII digests seemed to indicate that both of these isolates were 
correct, HindIII digests revealed an aberrant deletion in isolate A6 (Figure 10C). The DNA of 
isolate C9 was then transfected into U2OS cells to ensure that the modified vector genome 
remained capable of virus production. As shown in Fig 24, transfection produced an increasing 
number of green cells over time, indicating active virus production and spread. 
KBG isolate C9 was further modified to create KBG-ICP4-4xT124, abbreviated as ICP4-
miR124t, by inserting the previously validated miR124 response element (4xT124, Section 3.2) 
into the 3’ UTR of the ICP4 gene, as illustrated in Figure 7. In this instance I used a modification 
of the Gene Bridges-Red/ET protocol to facilitate the second step, removal of the selection 
cassette 56. A DNA fragment consisting of (i) the 3’UTR of the ICP4 gene with the insertion of 
4xT124, (ii) a kanamycin-selection cassette preceded by an I-SceI restriction site and flanked by 
direct repeats, and (iii) ICP4 3’ flanking sequence, was assembled and PCR amplified for 
replacement recombination with the homologous region of the ICP4 gene. Following kanamycin 
selection and confirmation of recombinants, removal of the selection cassette was performed by 
introduction of the arabinose-inducible I-SceI expression plasmid pBAD-ISceI into confirmed 
colonies, arabinose-induced linearization of the BAC DNA, and Red/ET-mediated recombination 
between the direct repeats flanking the kan gene. Intermediate (kanR) and final (kanS) products 
were confirmed by PCR and FIGE.  BAC DNAs from kanR colonies selected in the first step 
were examined by PCR using primers at the ends of the recombination fragment. The results 
showed that only eight of the 16 selected isolates (B, C, G, J, K, L, M, N, P) showed the 
expected 1.3-Kb band, while one isolate (A) amplified one 130-Kb band identical to the band 
amplified from the ICP4 3’UTR region of the KBG control without the 4xT124-ISceI-Kan 
insertion and five other isolates (4, 5, 6, 8, 9, 15) amplified both bands, the expected 1.3-Kb 
band plus the parental 130-bp band (Figure 15B). Of the 8 positive isolates two (ICP4-miR124t-
kan-B and ICP4miR124t-kan-C) were selected and compared to the original KBG backbone by 
FIGE analysis of MfeI, AflII or HindIII restriction digests. Restriction analysis of isolates B and C 
by FIGE indicated that both were correct (Figure 15C) and thus both were used for removal of 
the kan cassette. PCR analysis of isolates from this second step showed a band of the 
expected size (0.3 kb) in 4 isolates (ICP4-miR124t-B2, B3, B4, C1) out of six analyzed (Figure 
16B). All 4 isolates were then examined by FIGE of restriction digests, showing the anticipated 
patterns for 3 of the 4 (ICP4-miR124t-B3, B4, C1) (Figure 16C). Sequencing of these fragments 
confirmed their structure illustrated in Figure 16D. To clean the bacteria from the pBad plasmid, 
which presence could have interfered with the ability of the ICP4-miR124t-B3, B4, C1 BAC-
DNAs to make virus, the DNAs from the three positive recombinants ICP4-miR124t-B3, B4, C1 
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were re-electroporated in fresh DH10β electrocompetent cells and re-analyzed by FIGE 
restriction analysis after digestion with HindIII. As shown in Figure 17, 9 out of 10 isolates lost 
the pBad The DNA from isolate n10 was randomly selected and transfected into eukaryotic cells 
to make virus. Transfection of isolate KB-ICP4-miR124t-C1-2 (sample n°10 on the FIGE image, 
renamed ICP4-miR124t-BAC) into miR124-negative U2OS cells demonstrated that the vector 
modifications were compatible with virus growth (Figure 25). 
 
 
 
 
Figure 25: ICP4-miR124t BAC-DNA transfection into U2OS to verify BAC-DNA ability to generate virus. 
Following transfection, cells were incubated at 37°C in 5% CO2 and observed by fluorescence microscopy for eGFP 
expression every 24 h up to 72 h post transfection. Fluorescent pictures of actively replicating and spreading ICP4-
miR124t into infected cells were taken using a Nikon Diaphot  fluorescent microscope. 
 
 
3.3.2 Production of KG and ICP4-MIR124t viruses  
 
To generate the final oHSV-1 viruses to use for in-vitro and in-vivo testing, both KBG and ICP4-
miR124t BAC DNA were transfected into U2OS-Cre cells (generated in our laboratory by Dr. Y. 
Miyagawa) to eliminate the loxP-flanked BAC sequence [36,37] known to negatively affect viral 
growth 53.Loss of the BAC region, which also contains the lacZ reporter gene, was determined 
by staining the infected cells with X-gal. After limiting dilution of the U2OS-Cre derived viral 
supernatant on regular U2OS cells, one lacZ-negative viral clone was selected for both KBG-
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BAC removed (now referred to as KG) and ICP4-miR124t-BAC-removed (now referred as ICP4-
miR124t) viruses. Each viral clone was checked for clean removal of the region between the 
loxP sites by PCR with primers outside the LoxP region (Figure 18) and grown to high titer in 
regular U2OS cells.  
 
3.4 In Vitro Testing of ICP4-miR124T Vector for Growth Selectivity 
 
3.4.1 ICP4-miR124t replication efficiency in transiently miR124-
transfected cells 
 
 
Figure 26: ICP4-mir124t oHSV-1 replication efficiency after mir124 transient transfection. 
(A): Experiment schematic. Human U2OS cells were left untransfected or were transiently transfected either with pre- 
hu-pre-miR124-3 (Ambion) or hu-pre-miR137 (Ambion). 48 h later transfected and untransfected cells were infected 
with either KG or ICP4-miR124t. 48 h after infection the viral supernatant was collected and titered on regular U2OS 
to quantify virus yield. (B): oHSV-1 titration. ICP4-miR124t viral growth was first normalized to the growth of the 
control KB virus in untransfected, pre-miR124 transfected and pre-miR137 transfected cells. Data were then 
normalized to the growth of ICP4-miR124t in untransfected cells. The mean value ±standard deviations from four 
determinations are illustrated. The chart shows ICP4-miR124t inhibition in the presence of miR124 expression, but 
not of miR137, with a decrease in growth of six times compared to the growth of the same virus in the absence of 
miR124.  
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The efficiency of replication of ICP4-miR124t was compared to that of KG in the presence or 
absence of miR124 as summarized in Figure 26A. Human U2OS cells (negative for miR124) 
were left untransfected or were transiently transfected either with pre-hu-miR124-3 (Ambion 
AM17100-PM10691) or pre-hu-miR137 (Ambion AM17100-PM10513), a neuronal-specific 
miRNA for which the ICP4-miR124t virus had no responsive elements. 48 h later transfected 
and untransfected cells were infected with either KG or ICP4-miR124t. 48 h after infection, 
supernatants were collected and titered on U2OS cells to quantify virus yields. The experiment 
was done in quadruplicate to obtain statistically significant results. ICP4-miR124t viral growth 
was first normalized to the growth of the control KB virus in untransfected, pre-miR124 
transfected and pre-miR137 transfected cells. Data were then normalized to the growth of ICP4-
miR124t in untransfected cells. As shown in Figure 26B, ICP4-miR124t growth was reduced 
approximately 6-fold by miR124 expression. Moreover, ICP4-miR124t growth inhibition was 
miRNA specific as the expression of miR137 in the infected cells did not impair ICP4-miR124t 
viral growth. 
 
3.4.2 ICP4-miR124t replication efficiency in miR124-inducible stable cell 
lines 
 
To better quantify the miR124-dependent difference in viral growth between ICP4-miR124t and 
the KB control vector, stable miR-124-inducible cell lines were generated. An expression 
construct was created in which the promoter that controls miR124 synthesis is activated in 
response to treatment with tetracycline (Tet) or doxycycline (Dox). 
As shown in Figure 27, the Tet-On inducible system was comprised of a recombinant, 
tetracycline controlled transcription activator (rtTA) expressed from the rtTA gene that, following 
binding of Tet or Dox, interacted with tet operator (tetO) elements in an rtTA responsive 
promoter (Ptet) and induced the expression of the gene of interest under the control of this 
promoter. In the absence of Tet or Dox, rtTA was not able to bind to Ptet and the gene of 
interest was not expressed 61.  
The structures of the Ptet-miR124-rtTA construct and a related control construct expressing 
no miRNA are shown in Table 5. The Tet-miR124 and Tet-intron control constructs were 
transfected into U2OS cells to generate Tet-inducible miR124 expressing and control clones. 
Real-time RT-qPCR demonstrated different levels of miR124 in the highest miR124-expressing 
clones Tet-miR124-10 and Tet-miR124-84, with the former expressing 8.5 times more miR124 
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than the latter at 48 h after Dox treatment (Figure 28). Expression of miR124 in the control clone 
(Tet-negative-7) was several orders of magnitude lower and uninducible.  
 
 
 
 
Figure 27: Tet-inducible construct for Hu-mir124-3 expression. 
The Tet-On inducible system is comprised of a recombinant, tetracycline controlled transcription activator (rTta) 
expressed from the rTta gene that, following binding of tetracycline or its analog doxycycline, interacts with tet 
operator (tetO) elements in an rTta responsive promoter (Ptet) and induces the expression of the gene of interest, in 
this case pri-miR124, under control of Ptet. In the absence of tetracycline (or doxycycline), rTta cannot bind to Ptet 
and the gene of interest is not expressed. Specifically in TetO-miR124 construct, the addition of doxycycline activates 
rTta that binds to the TetO promoter and induces both pri-miR124 and puromycin resistance expression. Expression 
of both pri-miR124 and Puro can be modulated by Dox addition and depletion. 
 
 
The growth of KG and ICP4-miR124t viruses was tested in uninduced and induced Tet-
miR124-10, Tet-miR124-84 and Tet-negative-7 cells. As outlined in Figure 29, the cells were 
first treated with Doxycycline for 48 h or left untreated, and were then infected with KG or ICP4-
miR124t viruses at an MOI of 0.01 or 0.001. At 24, 48, 72 h post infection (hpi), viral 
supernatants were collected and titered on U2OS cells to quantify viral growth.  
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Figure 28: RT-qPCR for mir124 expression in U2OS TetO clones and in cells expressing endogenous miR124. 
The TetO-miR124 and TetO-intron constructs, which express the neomycin (neo) resistance gene, were transfected 
in U2OS cells to make a TetO inducible stable cell line. Single clones of stably transfected U2OS-Tet-miR124 and 
U2OS-Tet-control cells were then isolated through G418 selection and limiting dilution. Tet-miR124-10, Tet-miR124-
84 and Tet-negative-7 cell clones were tested for miR124 expression after doxycycline induction by RT-qPCR from 
total RNA extracted 48 h after Dox induction. 50B11 and PC12 were differentiated into neuronal cells through 
overnight Forskolin (F) treatment (50B11) or through a two weeks Nerve Growth Factor (NGF) treatment (PC12) 
Following treatment, cells were collected and tested for miR124 expression by RT-qPCR from total RNA extracted in 
presence or absence of the differentiating treatment. RT-qPCR from total RNA extracted from untreated SHSY5Y 
was also performed. The mean value ±standard deviations from three determinations are illustrated. The two different 
Tet-miR124 clones showed different levels of miR124 expression after Dox treatment, with clone Tet-miR124-10 
expressing 8.5 times more miR124 than Tet-miR124-84. Tet-negative-7 expressed no miR124 with or without 
Doxycycline treatment. Neither 50B1, nor PC12 nor SHSY5Y showed level of endogenous miR124 expression 
comparable to either doxycycline- induced Tet-miR124-10 or Tet-miR124-84.  
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Figure 29: ICP4-mir124t replication efficiency in TetO-mir124 stable cell lines. 
To examine potential effects of doxycycline-induced miR124 expression on oHSV-1 activity, both KG and ICP4-
miR124t viruses were tested in Tet-miR124-10, Tet-miR124-84 and Tet-negative-7 in presence or absence of a 48 h 
long doxycycline (Dox) treatment. One day before Dox treatment, Tet-miR124-10, Tet-miR124-84 and Tet-negative-7 
cells were plated as 50% confluent monolayers. 24 h later cells were treated with 10 µg/ml Dox for 48 h. Cells were 
then infected with either KG or ICP4-miR124t at two different MOIs, MOI= 0.01 or MOI= 0.001. At 24, 48, and 72 h 
post infection, cells and supernatants were collected and sonicated. Viral supernatants were then titered on U2OS 
cells to measure HSV replication.  
 
 
Both viruses grew at comparable rates in the Tet-negative-7 clone at both MOIs in the 
presence or absence of Dox (Figure 30A), as expected because no miR124 was expressed. 
The two viruses also grew at similar rates in both Tet-miR124-10 and Tet-miR124-84 cells in the 
absence of Dox treatment because no miR124 was expressed (Figures 30B-C). However, after 
Dox treatment, ICP4-miR124t viral growth was impaired in these cells while the growth of KB 
control virus was unaffected, indicating that the presence of miR124 specifically interfered with 
ICP4-miR124t replication (Figures 30B-C). Consistent with the RT-qPCR data (Figure 28), 
ICP4-miR124t viral replication was blocked up to 72 h after infection at both MOIs in clone Tet-
miR124-10, which expressed the highest levels of miR124, but not in clone Tet-miR124-84 
where, 72 h after infection at the higher MOI (MOI=0.1), miR124 expression was clearly not 
sufficient to inhibit ICP4-miR124t replication. However, 72 hpi at the lower MOI (MOI=0.01), 
ICP4-miR124t replication was still inhibited in clone Tet-miR124-84. These results indicated that 
there was a correlation between the amount of miR124 expressed by each clone and the 
degree of interference with ICP4-miR124t viral replication, with the stronger inhibition of ICP4-
miR124t virus associated with the higher expression of miR124 in clone Tet-miR124-10 
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Figure 30: ICP4-mir124t oHSV-1 replication efficiency in TetO inducible clones. 
(A): Viral replication in Tet-negative-7 control cells. Both ICP4-miR124t and KG viruses were able to grow at 
comparable rate at both MOI= 0.01 and MOI= 0.001 in presence or absence of doxycycline because no miR124 was 
expressed. (B): Viral replication in in tet-mir124-10 cells.  Both ICP4-miR124t and KG viruses were able to grow at 
comparable rate at both MOIs in absence of doxycycline because no miR124 was expressed. After doxycycline 
treatment the presence of miR124 in Tet-miR124-10 was able to interfere with ICP4-miR124t viral growth without 
affecting KB control virus at both MOI. (C): Viral replication in in tet-mir124-84 cells. Both ICP4-miR124t and KG 
viruses were able to grow at comparable rate at both MOIs in absence of doxycycline because no miR124 was 
expressed. After doxycycline treatment the presence of miR124 in Tet-miR124-84 clone was able to interfere with 
ICP4-miR124t viral growth without affecting KB control virus at the lower MOI = 0.001, but not at the higher MOI = 
0.01 where both Icp4-miR124t and KG viruses could replicate at the same rate. No standard deviation is available for 
this experiment.  
 
3.4.3 ICP4-miR124t replication efficiency in cells expressing endogenous 
miR124 
 
Human neuroblastoma SHSY5Y, rat DRG-derived 50B11 and rat pheochromocytoma PC12 
cells were chosen to test the replication efficiency of ICP4-miR124t virus in the presence of 
endogenous levels of miR124. SHSY5Y cells reportedly express elevated levels of miR124 
compared to many other cell lines 
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(http://www.microrna.org/microrna/getExprData.do?matureName=hsa-miR-
124&organism=9606), while 50B11 and PC12 cells may induce miR124 expression during 
differentiation into neuronal cells through overnight forskolin treatment (50B11) or through two 
weeks of NGF treatment (PC12). It should be noted that human and rat miR124 are identical in 
sequence and thus it was expected that ICP4-miR124t would be responsive to rat miR124. 
 
 
 
Figure 31: ICP4-mir124t oHSV-1 replication efficiency in cells expressing endogenous miR124. 
To examine potential effects of endogenous miR124 expression on oHSV-1 activity, both KG and ICP4-miR124t 
viruses were tested in 50B11, PC12 and SHSY5Y. One day before drug treatment, cells were plated at a 50% 
confluent monolayer. 24 h later cells were treated with either 75 µM Forskolin (Sigma), 50 ng/ml NGF (Sigma) or left 
untreated and incubated at 37ºC in 5% CO2 for as long as required by the specific differentiating treatment. One 
portion of the treated cells was used to quantify miR124 expression through RT-qPCR (Fig 28), while the rest of the 
cells were infected with either KG or ICP4-miR124t at the appropriate MOI (MOI= 0.1 for 50B11; MOI= 0.3 and 3 for 
PC12; MOI= 0.1, 0.01 and 0.001 for SHSY5Y cells). At different time-points after infection (24, 48, 72, 120, 196 h dpi 
for 50B11; 48 and 120 h dpi for PC12; 24, 48, 96 h dpi for SHSY5Y), cells and supernatants were collected and 
sonicated. Viral supernatants were then titered on U2OS cells to measure HSV replication. No standard deviation is 
available for this experiment. No difference in viral replication between KG and ICP4-miR124t was detected in any of 
the three cell lines.  
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SHSY5Y, 50B11 and PC12 were either left untreated or treated with the appropriate drugs 
to induce neuronal differentiation. Following treatment, cellular RNA was extracted to measure 
miR124 expression by RT-qPCR. As shown in Figure 28, endogenous miR124 levels in these 
cells were at least 1-2 orders of magnitude lower than the highest levels observed in Dox-
induced Tet-miR124-10 or Tet-miR124-84 cells. A viral growth experiment was then performed 
to determine if these relatively low levels of endogenous miR124 could interfere with ICP4-
miR124t replication. SHSY5Y cells were infected with either KG or ICP4-miR124t at MOIs of 
0.1, 0.01 and 0.001, and supernatants were collected at 24-72 hpi and titered on U2OS cells. 
Differentiated and undifferentiated 50B11 cells were infected at an MOI of 0.1 and supernatants 
collected at 24-120 hpi. Differentiated PC12 cells were infected at MOIs of 0.3 or 1.0 and 
supernatants collected at 48 and 120 hpi.  
As shown in Figure 31, there was no detectable difference in viral replication between KG 
and ICP4-miR124t in any of the three cell lines, indicating that the low levels of miR124 in these 
cell lines were not sufficient to control ICP4-miR124t replication. However, since miR124 
expression reduces the viability of cells in culture and the levels of miR124 in individual cells of 
the brain in vivo are not known, these results mainly pointed out that in vitro experiments 
couldn’t properly predict the behavior of ICP4-miR124t at the levels of miR124 existing in the 
brain. 
 
3.4.4 ICP4-miR124t replication efficiency in patient-derived primary 
glioma spheroid lines (GICs) in the presence or absence of induced miR124 
expression 
 
To test if ICP4-miR124t virus could replicate like KG control virus in GBM-derived cells, ICP4-
miR124t and KG viruses were used to infect two unrelated patient-derived primary glioma lines 
cultured as spheroids (GICs), GBM30 and Gli68 kindly donated by E.A. Chiocca (Ohio State 
University). Both cell lines were previously characterized by OSU colleagues for the absence of 
miR124 expression and their ability to form invasive tumors when injected into the brains of 
nude mice. These studies determined that animals injected with 2x105 cells of either line had an 
MST (mean survival time) between 20 and 30 days, meaning that both lines grew at 
approximately the same rate in vivo, allowing for better comparison of ICP4-miR124t viral 
growth between the two.  
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Since these cells were propagated as spheroid aggregates, the aggregates needed to be 
broken up into single cells to allow viral infection. The cells were then infected with either KB or 
ICP4-miR124t virus in suspension at an MOI=0.01 for two hours at 37oC and plated as single 
cell suspensions. Supernatants were collected at 24, 48 and 72 hpi and titered on U2OS cells.. 
As shown in Figure 32, ICP4-miR124t grew nearly as well as the KG control virus in both 
cell lines, reaching a titer that was 4.6 times lower than that of KG in Gli68 cells and only 2.6 
times lower than that of KG in GBM30 cells. 
 
 
 
 
Figure 32: ICP4-miR124t oHSV replication efficiency in patient-derived mir124-negative (GICs). 
On the day of the infection both GBM30 and Gli68 primary glioma spheroid cells aggregates, were broken up into 
single cells to allow viral infection. 2x105 cells were then counted and infected with either ICP4-miR124t or KG virus 
at MOI of 0.01. At 24, 48 and 72 h post infection, cells and supernatants were collected, and titered on U2OS cells. 
ICP4-miR124t grew nearly as well as the KG control virus in both cell lines, reaching a titer 4.6 times lower than KG 
in Gli68 and only 2.6 times lower in GBM30 at 72 h dpi. 
 
 
To confirm that ICP4miR124t replicated in these cells like the KG control virus because of 
the absence of miR124t, GBM30 and Gli68 cells were infected with lentiviruses expressing 
miR124 (Lenti-miR124) or miR137-antisense (Lenti-miR137A) as a control before super-
infection with either KG or ICP4-miR124t viruses, as illustrated in Figure 33A; lentiviral infection 
is a convenient method to express high levels of a transgene in poorly transfectable spheroid 
lines. The Lenti-miR124 virus was generated by cloning the intron-miR124-rPuro cassette 
derived from the earlier Tet-miR124 construct (see Figure 21 and table 5 for schematics) into a 
pCDH expression vector, transfection of the pCDH-miR124 plasmid together with three 
lentivirus packaging plasmids (PLP1, PLP2, PLP-VSVG) into 293T cells, and collection and 
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concentration of the supernatant. Plasmid pCDH-miR137A for expression of miR137-antisense 
(no response elements in ICP4-miR124t) was constructed in parallel and used to produce the 
control lentivirus. 
 
 
 
 
Figure 33: ICP4-miR124t oHSV replication efficiency in (GICs) following plenti-induced miR124 expression. 
(A): Experiment schematic. On the day of infection both GBM30 and Gli68 primary glioma spheroid cells aggregates, 
were broken up into single cells to allow viral infection. 2x105 cells were then counted and infected with either Lenti-
miR124 or Lenti-miR137A viruses at MOI of 5.0. before super-infection with either KG or ICP4-miR124t viruses. 24 h 
after infection cell medium was replaced with fresh medium and cells were selected with 30 µg/ml of puromycin 
expressed with miR124 from the lentivirus.  At 72 h after puromycin selection both cells were super-infected with 
either ICP4-miR124t or KG virus at an MOI of 0.01. At 48 and 96 h post infection, cells and supernatants were 
collected, and titered on U2OS cells. (B): Viral titrations. ICP4-miR124t virus was completely inhibited by expression 
of miR124, in both GBM30 and Gli68 cells, without being affected by the presence of miR137A, while KG control 
virus could replicate with no difference both in presence or absence of either miR124 or miR137A.  
. 
 
To examine potential effects of lentiviral miR124 expression on the cells, such as neuronal 
differentiation or reduced cell viability, one of the cell lines, Gli68, was initially infected with 
Lenti-miR124. 24 h after infection, cells were selected with puromycin whose resistance gene 
was jointly expressed with miR124 from the pCDH plasmid. Cells maintained their spheroid 
phenotype without any sign of change, continuing to replicate well throughout the length of the 
experiment. At 72 h after puromycin selection (96 hours after initial Lenti-virus infection), cells 
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were collected and total RNA was extracted to measure miR124 expression by RT-qPCR. The 
results were normalized to miR124 expression levels in U2OS cells that do not express miR124 
(Figure 28). As shown in Figure 34, there was a very strong 3.5 logs increase in miR124 
expression in Lenti-miR124 infected Gli68 cells compared to uninfected cells, demonstrating the 
feasibility of lentivirus-mediated exogenous miRNA expression in primary GICs.  
 
 
 
 
Figure 34: RT-qPCR of miR124 expression in Lenti-miR124 infected Gli68. 
On the day of the infection Gli68 primary glioma spheroid cells aggregates, were broken up into single cells to allow 
viral infection. 2x105 cells were then counted and infected with Lenti-miR124 at MOI of 5.0. 24 h after infection cell 
medium was replaced with fresh medium and cells were selected with 30 µg/ml of puromycin which resistance was 
expressed together with the miR124 gene from the lentivirus. At 72 h after puromycin selection cells were collected 
and total RNA was extracted to measure miR124 expression relative to RNU43, a small RNA used as internal control, 
through RT-qPCR. Data were normalized by miR124 expression in U2OS, which didn’t express any miR124 as 
illustrated in Figure 28. The mean value ±standard deviations from three determinations are illustrated. The chart 
shows a very strong 3.5 logs increase in miR124 expression in Lenti-miR124 infected Gli68 cells.  
 
 
Both GMB30 and Gli68 cells were then infected with either Lenti-miR124 or Lenti-miR137A 
at an MOI of 5 to ensure that most of the cells would get infected. Puromycin selection was 
initiated 24 hours after infection and 72 h later (96 h after lentivirus infection), cells were super-
infected with either ICP4-miR124t or KG virus at an MOI of 0.01. Supernatants were collected at 
72 and 96 h post super-infection and titered on U2OS cells to measure HSV replication. As 
shown in Figure 33B, in both cell lines ICP4-miR124t viral growth was completely inhibited by 
miR124 expression, while remaining unaffected in the presence of miR137A. KG control virus 
instead replicated equally efficiently in presence and absence of either miR124 or miR137A. At 
96 h after HSV infection, the ICP4-miR124t titer was 3x103 times lower in miR124-expressing 
GBM30 cells than in the miR137 control cells. A very similar result was evident in Gli68 where 
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the titer of ICP4-miR124t at 96 h after infection was 3.5x103 times lower in miR124 expressing 
cells than in the miR137A expressing cells. 
In conclusion, these data show that ICP4-miR124t virus can grow and replicate like KG virus 
in GBM-derived cells in vitro, but its growth is completely inhibited when these same CNS-
derived tumor cells are induced to express miR124.  
 
3.5 In Vivo Testing of ICP4-miR124T Virus for Growth Selectivity 
 
The ICP4-miR124t viral response to endogenous levels of miR124 was assessed in vivo, a 
preferred read-out as the diversity of normal brain cells cannot be faithfully recapitulated in vitro.  
Toxicity studies were performed to evaluate potential immunologic and pathogenic effects 
on normal brain in both tumor-free, immunocompetent BALB/c mice and tumor-free 
immunocompromised nu/nu nude BALB/c mice. 
 
3.5.1 Toxicity testing for virus safety in immunocompetent mice 
 
In the first in vivo experiment, either KG control virus or ICP4-miR124t virus was administered 
into the brains of 3 weeks old female immunocompentent BALB/c mice for a total of three mice 
per virus (Figure 35A).  
For each virus one single dose containing 4.8x109 genome copies (gc) was tested through 
injection of each mouse with 4µl of viral prep. Two animals, one for each virus, were sacrificed 3 
h post injection (hpi), while the remaining animals were left alive and monitored for general 
health. The 3 hpi timepoint was taken to measure how much of the viral DNA injected as virus 
particles could be recovered by DNA extraction from total mouse brain. As illustrated in Figure 
35B, the first KG treated mouse was sacrificed at day 5 after injection because of extreme 
weight loss and signs of discomfort. One ICP4-miR124t injected mouse was also sacrificed at 
the same time. The second KG injected mouse was sacrificed at day 7 after injection, while its 
ICP4-miR124t injected counterpart was left alive and continues to be monitored for general 
health. DNA was extracted from whole brain of the sacrificed animals and qPCR was performed 
using primers and probe specific for the viral glycoprotein D (gD) gene to determine the number 
of viral genome copies compared to input virus. The 7 dpi timepoint was chosen because after 
being sick for the first 5 dpi, the KG-injected mouse started to show signs of recovery and I 
wanted to check if this behavioral change was corresponding to a change in viral yield. As 
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shown in Figure 35C, the amount of viral DNA recovered from the brain at 3 hpi was 
significantly lower than the injected amount and varied between the two viruses, indicating the 
presence of a systematic error caused by the injection and/or DNA isolation procedure 
 
 
 
 
Figure 35: In vivo toxicity testing of ICP4-miR124t for vector safety in immunocompetent mice. 
(A): Experiment schematic. Either KG or ICP4-miR124t was administered by intracranial stereotactic injection into the 
right temporal lobe (cortex) of 3 weeks old female BALB/c mice for a total of three mice per virus. A single 4µl dose of 
each virus (4.8x109 gc /animal) was injected in each mouse. (B): survival results: animals were monitored for general 
health (weight, activity, clinical signs) every other day up to 28 days after injection. KG-N was sacrificed at day 5 after 
injection because of extreme weight loss and other signs of viral-related pathology. ICP4-miR124t –L injected mouse 
was also sacrificed at the same timepoint. KG-R injected mouse was sacrificed at day 7 after injection, while ICP4-
miR124t-B, its injected counterpart, was left alive and monitored to these days (19 dpi) for general health. This mouse 
is still healthy. (C): qPCR on injected animal brains. Total DNA was collected from the brain of each sacrificed animal 
and qPCR was performed using specific primers for the HSV glycoprotein D (gD) gene to determine the number of 
viral genome copies compared to the input. The mean value ±standard deviations from three determinations are 
illustrated. Results show that he amount of KG virus in the mouse brain 3 hpi was significantly lower than the amount 
injected, and varied between the two viruses, indicating the presence of a systematic error caused by the injection 
procedureand/or the DNA extraction procedure. Results also show that the amount of KG virus in the mouse at day 
five post injection was 5.9 times higher than the amount of KG present in the brain at 3 hpi (T0), while the amount of 
ICP4-miR124t virus present in the mouse brain at day 5 post injection was 3.3 times lower than the amount present 
at T0, indicating that only KG but not ICP4-miR124t was able to replicate up to 5 days after injection. At day 7 post 
injection the amount of KG present in the brain had diminished compared to day 5, a sign that, after having caused 
severe sickness in the mice in the first 5 days, also the KG control virus eventually had stopped replicating.  
 
 
From this result it was clear that the amount of viral genome copies at 3 hpi was a better 
reference for comparison with the amounts of DNA isolated at later timepoints than the injected 
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amount. The 3 hpi timepoint was thus considered as time-zero (T0) to which all the other qPCR 
results of this experiment were compared. Figure 35C shows also that the amount of KG virus 
present in the mouse brain at day 5 post injection was 5.9 times higher than the amount of KG 
present in the brain at T0, while the amount of ICP4-miR124t virus at day 5 post injection was 
3.3 times lower than the amount at T0, indicating that only KG but not ICP4-miR124t was able 
to replicate up to 5 days after injection. However, at day 7 post injection the amount of KG 
present in the brain had diminished compared to day 5, an indication that, after having caused 
signs of disease in the mice in the first 5 days, the KG control virus had stopped replicating, 
most likely blocked by the host antiviral immune response. This result was consistent with the 
weight and clinical signs of the KG-injected mouse sacrificed on day 7; after losing 20% of its 
weight and showing discomfort and impaired behavior up to day 5 post injection, on day 7 this 
mouse had gained weight and was behaving more normally.  
These results proved that at high virus doses, ICP4miR124t was safe in immunocompetent 
mice where it was never able to replicate and cause disease. Instead the KG control virus, 
lacking miR124 responsive elements, was clearly more toxic, causing disease in the injected 
mice for the first 5 days post infection before being blocked by the host immune system.  
 
3.5.2  Toxicity testing for virus safety in immunodeficient mice 
 
The second in vivo experiment was performed in an immunodeficient mouse model to try to 
emphasize the toxic effect of the KG control virus. Using the same procedure described above, 
KG or ICP4-miR124t viruses were administered by intracranial stereotactic injection into the 
right temporal lobe of 3 weeks old female nu/nu BALB/c mice for a total of four mice per virus 
(Figure 36A). One single dose of 1.5x 109 gc of each virus was tested by injecting each mouse 
with 4µl of viral prep. 
At day 5 after injection, three out of four animals treated with KG control virus had died, 
while all the mice treated with ICP4-miR124t were still alive and healthy (Figure 36B). At this 
point, total DNA was collected from the brain of the last very sick KG-treated animal and of one 
sacrificed ICP4-miR124t-treated animal and qPCR for HSV genomes was performed as above 
to determine the number of viral genome copies compared to the injected input. The remaining 
ICP4-miR124t treated animals remained symptom-free until sacrifice on days 14, 21 and 33 
after injection and the same procedure was followed to quantify viral genomes in the brains of 
these sacrificed animals.  
 75 
 
 
 
 
Figure 36: in vivo toxicity testing of the ICP4-miR124t oHSV-1 for vector safety in immunodeficient mice. 
36A: Experiment schematic. Either KG or ICP4-miR124t was administered by intracranial stereotactic injection into 
the right temporal lobe (cortex) of 3 weeks old female nu/nu nude BALB/c mice for a total of four mice per virus. A 
single 4µl dose of each virus (1.5x109 gc /animal) was injected in each mouse. 36B: survival results. At day 5 after 
injection, three of the four animals treated with KG control virus had died, and the last one very sick was promptly 
sacrificed. Instead, all the mice treated with ICP4-miR124t were still alive and healthy. One ICP4-miR124t treated 
animal was then sacrificed, while the remaining ICP4-miR124t animals were sacrificed at days 14, 21 and 33 for 
qPCR analysis to determine the number of viral genome copies present in the brain of each animal compared to one 
deceased KG injected animal and to the input virus injected at T0. 36C: qPCR on injected animals brains.  Total DNA 
was collected from the brain of each sacrificed animal and qPCR was performed using specific primers for the HSV 
glycoprotein D (gD) gene to determine the number of viral genome copies compared to input. The mean value 
±standard deviations from three determinations are illustrated. qPCR data show that the amount of KG virus at day 5 
post injection was 1.5 times higher than the amount injected (day 0), while the amount of ICP4-miR124t virus at day 5 
post injection was 7.6 times lower than the injected amount, further decreasing to a 3,000-fold difference at 33 day 
post injection.  
 
 
The results in Figure 36C show that the amount of KG virus at day 5 post injection was 1.5 
times higher than the amount injected (day 0), most likely a underestimate given that the 
amount of virus injected was used as T0 rather than the amount of virus recovered from animal 
brains at 3 hours post injection as in the first in vivo experiment. In contrast, the amount of 
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ICP4-miR124t virus at day 5 was 7.6 times lower than the injected amount, further decreasing to 
a 3,000-fold difference at 33 dpi. These results demonstrated that at high virus doses, 
ICP4miR124t remained safe in immunocompromised mice while KG lacking miR124 response 
elements was lethalin these animals.  
In conclusion these data demonstrate that the presence of miR124-responsive elements in 
the viral backbone make the oHSV-1 safer and less toxic in both immunocompetent and nude 
mice. 
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4 DISCUSSION 
 
 
 
GBM is the most common form of glioma and no cure exists. The current standard treatment 
that includes surgical resection of the tumor mass followed by radiotherapy and chemotherapy 
on average increases the patient’s lifespan by only a few months, indicating an urgent need for 
new treatments of this deadly disease2-4.  
OVs are attenuated lytic viruses specifically designed to infect and kill only tumor cells 
without affecting the surrounding normal tissue7. OVs derived from Herpes Simplex Virus type-1 
(oHSVs), made tumor-selective through the deletion of one or more genes that are dispensable 
for HSV-1 growth in cancer cells, but that are required for efficient replication in normal cells, 
have been employed as promising alternatives to standard ineffective GBM treatment7. 
However, while results from clinical trials have demonstrated that these oHSV are safe for 
patients, they are too attenuated to efficiently eradicate GBM2-4,17. To overcome this problem, I 
developed a new kind of oHSV named ICP4-miR124t that differs from previously described 
oHSVs in that it is not deleted for any genes but derives its tumor selectivity from the different 
pattern of miRNA expression between tumor and normal brain5,33,62-65. Indeed by bringing the 
activity of its essential ICP4 gene under the control of miR124, a miRNA expressed only in 
normal neurons and microglia but completely absent in tumor cells66,67, I demonstrated that this 
novel ICP4-miR124t oHSV was able to replicate as strongly as its non-controlled counterpart in 
tumor cells that don’t express miR124, while its replication was essentially shut down in cells 
that produce miR124. MiR124 was chosen because its expression correlates directly with 
terminal differentiation and inhibition of cellular proliferation and is incompatible with 
maintenance of the tumor phenotype and the viability of glioma cells where miR124 is not 
naturally expressed41,42. As a consequence, glioma cells cannot up-regulate miR124 without 
losing their tumorigenicity(http://www.microrna.org/microrna/getExprData.do?matureName=hsa-
miR-124&organism=9606)43,62,68.  
Since the start of my study, reports have begun to appear in the literature describing similar 
approaches to selectively allow lytic replication of different viruses in tumor cells69-73. Target 
sequences for tumor-specific miRNA let-7, p53-responsive antiviral-RNAi or liver-specific 
miR122 have been employed to engineer oncolytic adenovirus for hepatocellular carcinoma 
therapy 70-73. Target sequences for tumor-specific let-7 miRNA have also been engineered in a 
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vaccinia virus backbone created to specifically replicate in a panel of several tumor cell lines 
representative of a wide range of human cancers74.Target sequences for brain-specific miR125 
have been used to generate a oncolytic vesicular stomatitis virus (oVSV) that replicates 
efficiently in tumor cells but is less neurotoxic than its wild-type counterpart. Target sequences 
for muscle-specific miR133 and miR206 have been engineered into an oncolytic picornavirus 
genome in an attempt to reduce its toxicity 75. Target sequences for the brain specific miR7 
have been used to engineer a measles oncolytic virus for the therapy of GBM76. Also an 
amplicon HSV-1 has been successfully targeted to respond to tumor-specific miRNA expression 
by inserting prostate-specific miR143 and miR145 target sequences in the 3’UTR of the HSV-1 
essential ICP4 gene, confirming my observations that this gene is a suitable target for miRNA–
controlled replication of oHSV-152 Consistent with all this literature data, my work illustrates that 
it is possible to engineer HSV to bring its replication under the control of miR124. What I 
showed in this study is that indeed my miR124-regulated ICP4-miR124t oHSV replicates in and 
kills tumor cells as effectively as non-regulated virus without being toxic for normal brain, 
suggesting that it can be used as a tool for the treatment of GBM. 
The first step to create a miR124-controlled oHSV consisted of engineering and testing a 
miR124 responsive element able to regulate ICP4 protein expression when inserted into the 
3’UTR of the ICP4 gene. A tandem of four miR124 target sequences (4xT124), each separated 
from the next by three different 7-8 nucleotides long spacers, was created according to a design 
already demonstrated by others to maximize the miRNA effect on the target gene49-52. When 
inserted in the 3’UTR of a luciferase reporter gene, this miR124 responsive element proved to 
be extremely effective in responding to the specific presence of miR124 in more than one cell 
line (see Figure 23). 
The second step consisted of engineering the HSV-1 genome to insert the 4xT124 element 
in the 3’UTR of the ICP4 gene. To create the final ICP4-miR124t oHSV I took advantage of a 
BAC construct containing a more stable joint-deleted version of the HSV-1 genome already 
containing the gB:NT mutation recently shown to improve HSV-1 initial infection by accelerating 
viral entry57. As part of a BAC, the HSV-1 genome can replicate in bacteria rendering all 
manipulations of the virus much faster and easier than in the past, allowing the design and 
engineering of multiple modifications of the same backbone with relative ease compared to the 
past 56. In addition, the absence of the joint, by freezing the viral genome in one of its isoforms 
and by maintaining only one copy of each of the diploid HSV-1 genes (see section 3.1 and 
Figure 5), stabilized the vector against undesired recombination events and facilitated accurate 
engineering of the viral vector without affecting the ability of the virus to kill tumor cells 
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compared to non-deleted virus (see Figure 22). The insertion of both the T2A-eGFP sequence 
in frame with gC and the 4xT124 responsive element in the 3’UTR of ICP4 were done in two 
fairly quick steps using Red/ET based recombination techniques yielding very clean 
recombination products that were easy to check for accuracy by PCR and FIGE analysis to 
exclude unwanted changes that would have gone undetected in the past (see Figures 9-10, 15-
17). A functional ICP4-miR124t-BAC oHSV virus was then obtained from the BAC-DNA through 
transfection into U2OS cells that produced actively replicating and spreading green fluorescent 
virus (see Figure 25). ICP4-miR124t-BAC DNA was then finally transfected into U2OS-Cre to 
free the oHSV-1of BAC sequences known to negatively affect viral growth. Also this last 
modification was very easy to check for accuracy by PCR (see Figure18). Therefore in this first 
part of the study I demonstrated that the modification of the HSV-1 genome by Red/ET 
mediated recombination in bacteria is a very convenient way to modify and improve the virus for 
clinical purposes compared to the slow and tedious classical in-cell recombination strategies. 
The third step of the work consisted of testing the response of ICP4-miR124t to miR124 
expression. Several different in vitro approaches were used. Initially I performed a transient 
transfection on U2OS cells with either pri-miR124 or another pri-miRNA one day before infection 
with either ICP4-miR124t or its non-regulated counterpart KG. The results showed that ICP4-
miR124t replication was reduced by the transient expression of miR124 but not of another 
miRNA, while KG viral growth was not affected by the presence of miR124 (see Figure 26). 
However, this experiment had two limitations. First, like all small RNAs, miR124 is unstable in 
vitro and was quickly degraded after transfection. Second, transient transfection is not 100% 
efficient and not all the cells expressed miR124. In the cells that did express the miRNA, the 
amount varied, reducing the overall effect on ICP4-miR124t replication. To obtain stronger 
evidence of the inhibitory effect of miR124 on ICP4-miR124t replication and to overcome the 
limitations of a pri-miRNA transient transfection, I generated stable U2OS cell lines for 
doxycycline-inducible controlled expression of miR124. In two different clones, induced 
expression of miR124 48 h before infection greatly reduced ICP4-miR124t viral growth 
compared to the growth of KG, its non-miRNA-regulated viral counterpart. In both clones this 
inhibitory effect was not observed in the absence of Dox pre-treatment and was dependent on 
the amount of miR124 expressed relative to the amount of virus used for the infection (Figures 
30). Specifically, induced TetO-miR124-10 cells expressing the higher level of miR124 (Figure 
28) were able to block ICP4-miR124t viral replication after infection at both low and high MOI, 
while induction of the TetO-miR124-84 clone producing less miR124 blocked replication only at 
the lower MOI. These results pointed out that in order to efficiently block ICP4-miR124t 
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replication, it was necessary for a cell to express a certain amount of miR124 capable of 
handling the amount of virus present, confirming results already published by others that the 
higher the expression of a given miRNA, the higher the fold suppression of its target mRNA51.  
Having confirmed that ICP4-miR124t viral growth could effectively be regulated by 
exogenous miR124 expression, I next designed experiments to understand the behavior of 
ICP4-miR124t in response to endogenous levels of miR124. Initially I tested ICP4-miR124t 
replication in SHSY5Y cells that endogenously express elevated levels of miR124, but I found 
that these cells were unable to block viral replication. Determination of the amount of miR124 in 
these cells showed that it was lower than that in either of the induced miR124-expression clones 
(Figure 31). Therefore I concluded that the miR124 level in SHSY5Y was probably below the 
threshold necessary for a measurable effect on ICP4-miR124t replication. An explanation of this 
result could be that it is known from the literature that miRNA expression has to exceed a 
certain level to efficiently suppress its target mRNA51 and the amount of miR124 expressed in 
SHSY5Y cells was below this threshold. Another possible explanation could be that not all 
miR124 present in SHSY5Y is active. Recently presented data 
(http://www.abstracts2view.com/asgct/view.php?nu=ASGT12L1_99) have elegantly 
demonstrated that not all the miRNAs expressed in a cell are active. Therefore the detection of 
an miRNA in a certain cell type by RT-qPCR does not guarantee that this miRNA is active when 
checked for its ability to regulate the expression of its target gene. In the case of SHSY5Y, this 
kind of explanation wouldn’t be surprising considering that miR124 is a key player in neuronal 
differentiation by controlling the cell’s ability to progress throught the cycle via direct regulation 
of CDK641,42. Tumor cells like SHSY5Y replicate actively in vitro and thus cannot have high 
levels of activity of an miRNA like miR124 that induces terminal differentiation. Expression of 
endogenous miR124 was also evaluated in two other cell lines, 50B11 and PC12, after 
induction of neuronal differentiation according to published protocols47,48. However, RT-qPCR 
analysis (Figure 31) showed that these procedures did not induce miR124 levels that were 
higher or even as high as in SHSY5Y . Consistent with this result, ICP4-miR124t viral growth 
was not blocked in either of these two cell lines with or without differentiation treatment, 
reaffirming that miR124 levels below those observed in Dox-induced miR124-expression clones 
could not significantly reduce ICP4-miR124t viral replication in cultured cells. 
Although SHSY5Y cells express elevated levels of miR124 when compared to many other 
cell lines, these levels are much lower than those in adult brain 
(http://www.microrna.org/microrna/getExprData.do?matureName=hsa-miR-
124&organism=9606), suggesting that in vitro experiments like the ones described above could 
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not properly predict the behavior of ICP4-miR124t in the brain. Therefore the ICP4-miR124t viral 
response to endogenous levels of miR124 in the brain had to be assessed in vivo, a preferred 
read-out also because the diversity of brain cells cannot be faithfully recapitulated in cell culture. 
The miR124-hairpin sequence is very well conserved throughout evolution and human and 
murine hairpins perfectly overlap 34, making mice a suitable animal model to test the behavior of 
ICP4-miR124t in response to the levels of miR124 existing in the brain.  
ICP4-miR124t was tested in both an immunodeficient and an immunocompetent mouse 
model. In the first experiment, healthy immunocompetent mice were inoculated in the brain with 
the highest possible dose of either ICP4-miR124t or its non-miR-regulated counterpart KG. 
Brains were collected at different timepoints after injection to quantify through qPCR the amount 
of viral DNA present over time. One ICP4-miR124t mouse was left alive and to date has shown 
no adverse effects of the viral inoculation. The decrease in the amount of ICP4-miR124t viral 
DNA over time (~5 times reduced at 5 days after injection (dpi) clearly demonstrated the 
inability of the virus to effectively replicate in healthy brain in vivo (Figure 35C). This was in 
contrast with the results obtained from the KG control virus where the viral DNA amount 
increased ~6 times in the first 5 dpi. Interestingly, however, the amount of KG DNA then 
decreased in the next 2 days to the level immediately after inoculation (T0), indicating that the 
virus had stopped replicating, most likely blocked by the murine immune system. Consistent 
with these results, while both ICP4-miR124t treated animals looked healthy throughout without 
any weight loss or manifestation of disease (Figure 35B), KG treated animals looked extremely 
sick for the first 5 days after injection before the remaining animal showed signs of recovery. 
This experiment demonstrated that ICP4-miR124t oHSV was very safe and non-toxic when 
injected into healthy brain, where the endogenous levels of expressed miR124 were clearly 
sufficient to block its replication even after injection of a very high dose. In contast, KG control 
virus caused severe toxicity for the first 5 dpi because of its lack of miR124 responsive 
elements. 
In the second experiment, healthy immunodeficient mice were inoculated in the brain with 
the highest possible dose of either ICP4-miR124t or its non-miR-regulated counterpart KG. At 5 
dpi three out of four KG injected mice had died, while all the ICP4-miR124t treated animals 
were alive and healthy, a first demonstration that miR124-mediated control of viral replication 
was effective in eliminating toxicity associated with HSV-1 growth in normal brain (Figure 36B). 
These observations were in line with the qPCR data obtained from the brains of the animals that 
survived viral injection, showing an opposite behavior between KG control virus, whose genome 
copies increased compared to the amount of injected virus, and ICP4-miR124t, whose genome 
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copies gradually decreased over time after injection (Figure 36C). These results demonstrated 
how much safer ICP4-miR124t oHSV-1 was compared to its unregulated counterpart KG in an 
immunodeficient mouse model where the absence of a functional immune system made KG 
extremely toxic. 
This very positive result confirms data from the literature that have shown that non-neuronal 
cells, specifically glia and neuronal precursor cells (NPCs) that do not express the neuronal-
specific miR124 33,35-37, are not favorable to HSV replication in vivo. Non-neuronal cells have 
been investigated for susceptibility to HSV-1 infection and all of them can be infected by HSV-1 
given that HSV-1 receptors (nectin-1, HVEM, 3-OS HS) are expressed in virtually all cells 77-79. 
However data from the literature have shown that following in-vivo infection of mouse brains 
with high doses of HSV-1, the cells which predominantly express HSV-1 proteins are neurons, 
while in non-neuronal cells HSV-1 proteins are almost undetectable 77. The reason why in-vivo 
HSV-1 viral infection seems to involve mainly neurons is not know and needs to be further 
investigated, but this observation may well explain the absence of toxicity detected for ICP4-
miR124t following injection in mouse brains. Nonetheless, to further reduce the possibility of 
brain toxicity caused by potential oHSV-1 infection of non-neuronal cells, it is possible in the 
future to further modify ICP4-miR124t oHSV to have multiple miRNA target sequences 
regulating the expression of ICP4 and/or ICP27 HSV-1-essential genes, each one responding to 
a specific non-neuronal miRNA (e.g., miR219 or miR338 for oligodendrocytes, miR23 or miR29 
for astrocytes, miR7 for NPCs)33. For example, target sequences for one or more of these other 
miRNAs can be added to the miR124 responsive element in ICP4 to expand the regulation of 
viral replication to additional cells types. A similar design with a tandem of target sequences for 
multiple miRNAs has already been described and validated in the literature80. Alternatively, a 
tandem of identical target sequences for a different miRNA can be inserted in the 3’UTR of 
ICP27 to regulate the expression of this other essential HSV IE gene, a design already 
successfully tested in our laboratory (unpublished data). A different strategy to reduce oHSV 
toxicity to the normal brain while increasing viral specificity to the tumor would be retargeting 
ICP4-miR124t to be able to enter cells by recognizing a receptor specifically expressed only on 
tumor cells, another design successfully developed in our laboratory using the human epidermal 
growth factor receptor (EGFR) widely expressed on GBM cells (H. Uchida et al, submitted for 
publication). This strategy can be combined with miRNA-mediated regulation of HSV replication. 
Despite the fact that ICP4-miR124t was absolutely non- toxic after injection in the animals a 
major safety concern isthe possibility that the oHSV could lose or mutate part or the entire 
4xT124 responsive element in ICP4 and revert to an unregulated replication-competent virus, 
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an occurrence already described in the literature with a similar miRNA-regulated flavivirus81. 
The odds for this to happen in ICP4-miR124t oHSV1 were considered small because the 
4xT124 responsive element was designed to be so close to the ICP4 stop codon that a 
recombination event in that area would have most likely affected the ICP4 coding sequence, 
creating a replication-defective virus. However, internal recombination events within the 4xT124 
element cannot be excluded and these could cause the loss of half or more of the four identical 
miR124 target sequences, potentially leaving the ICP4 gene with too few target sequences to 
be effectively regulated by miR124. To minimize this possibility, the 4xT124 responsive element 
in ICP4-miR124t could be modified to move the respective copies of the target sequence farther 
apart and/or by mixing in target sequences for other miRNAs. These modifications can 
potentially improve the ICP4-miR124t design given that both kinds have already been shown to 
be very effective in reducing the occurrence of recombination events in other viral systems80. 
In the final step of this study, ICP4-miR124t virus was tested in vitro for efficacy in killing 
GBM cells through lytic replication to ensure that the presence of the 4xT124 responsive 
element in the ICP4 3’UTR didn’t impair the ability of the virus to replicate in tumor cells 
compared to its non-regulated counterpart KG. The primary human GBM-derived cells (GICs) 
used for this purpose, GBM30 and Gli68, are both representative of the mesenchymal molecular 
subtype of GBM (E.A. Chiocca, personal communication), the most common of the four GBM 
kinds according to the Verhaak classification6. Compared to established GBM cell lines like U87, 
SNB19 or U251 routinely used in the past, GICs represent a much better model of GBM for both 
in vitro and in vivo studies because they grow in culture in suspension as multipotent spheroid 
aggregates, and when injected into immunocompromised animals, they form highly invasive 
brain tumors closely resembling human GBM. On the contrary, most of the established GBM 
cell lines grow as monolayers in culture and don’t form invasive tumors in vivo. This is an 
important distinction, since key issues with current GBM therapy include the inability to cleanly 
resect the tumor mass and to reach migrating cells by focused radiation. ICP4-miR124t efficacy 
data on GICs cells in culture were very encouraging. Specifically, the virus was able to infect 
and replicate as efficiently as its non-regulated viral counterpart KG in both Gli68 and GBM30 
cells, ultimately killing all cells (Figure 32). This result is very important because the goal of my 
study was to develop a new oHSV that was safer than wild-type HSV-1 virus when injected in 
the brain, but not impaired for tumor cell killing, unlike current oHSVs, which are safe but whose 
replication efficacy in tumor cells is reduced compared to wild type virus because of  the 
removal of virulence genes like ICP34.52,4. To confirm that vigorous ICP4-miR124t viral 
replication in GICs was possible only because of the absence of miR124, a lentivirus was used 
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to express miR124 in both Gli68 and GBM30 before super-infection with ICP4-miR124t. The 
results of these experiments showed that ICP4-miR124t viral replication was greatly impaired in 
both GICs by prior infection with lenti-miR124, but not by prior infection with a lentivirus 
expressing an unrelated miRNA (Figure 33) 
Together, my results have shown that introduction of the 4xT124 responsive element into 
the ICP4 3’UTR is a very effective strategy to impede viral replication in normal brain cells 
without decreasing the ability of the virus to efficiently replicate in and kill GBM tumor cells 
compared to non-miRNA-regulated virus. However, replication efficiency is not the only 
determinant of the therapeutic efficacy of oncolytic viruses and the design of ICP4-miR124t 
oHSV can be further modified to address other impediments to successful therapy. One of the 
biggest limitations in the use of oHSV for the treatment of GBM is viral spread away from the 
site of injection to reach all tumor cells, given that one problematic characteristic of GBM cells is 
their ability to migrate away from the tumor core and infiltrate the surrounding normal tissue. 
Data from clinical trials have indeed highlighted that oHSV can only reach the tumor cells that 
are closest to the site of injection, mainly because of the thick tumor extracellular matrix (ECM) 
that physically traps the virus and impedes its spread. To address this problem, the oHSV could 
be de-targeted to eliminate the elements of HSV glycoproteins B and C that bind to heparan and 
chondroitin sulfates, abundant components of the ECM contributing to oHSV entrapment in the 
ECM82,83. Moreover, the virus could be armed with genes expressing metalloproteinases 
capable of degrading the ECM84.The HSV-1 genome is large and contains multiple regions that 
are not essential for efficient viral growth and that can thus be substituted with transgenes to be 
expressed at the site of infection85-87. Finally, the oHSV could be armed with transgenes for 
molecules that are able to activate the host immune system against infected tumor cells88,89. 
In summary, the results of this study indicate that it is possible to produce a safe oHSV that 
is effective against GBM by regulating one or more of its essential genes to be only expressed 
in tumor cells while maintaining the full complement of viral genes without attenuating deletions. 
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